Jasonyoyoo的个人主页 - 老虎社区

Jasonyoyoo

Jasonyoyoo

暂无个人介绍

IP属地：未知

34关注

0粉丝

0主题

0勋章

2021-07-13

Good! Help like thanks

抱歉，原内容已删除

2021-07-11

Best. Help like please

Could The iPad Be Apple’s Best Performer in Fiscal Q3?<blockquote>iPad 会成为苹果第三财季表现最好的产品吗？</blockquote>

2021-07-07

Like plz

Mark Wahlberg-backed F45 targets over $1.5 bln valuation in U.S. IPO<blockquote>马克·沃尔伯格支持的 F45 美国 IPO 估值超过 15 亿美元</blockquote>

2021-07-07

Sad

抱歉，原内容已删除

2021-06-30

Like my comment please tq!

抱歉，原内容已删除

2021-06-30

Very good

These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday<blockquote>这两家纳斯达克生物技术公司周二做出了令人瞠目结舌的举动</blockquote>

2021-06-27

$Fastly, Inc.(FSLY)$gooooood

2021-06-20

Yay

抱歉，原内容已删除

2021-06-20

Oh no

抱歉，原内容已删除

2021-05-04

😕

抱歉，原内容已删除

2021-05-04

❤️👍👍👍💪💪💪👌

2021-05-02

👍

1 Question Tesla Investors Need to Ask Themselves<blockquote>特斯拉投资者需要问自己的一个问题</blockquote>

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3577446101921159","uuid":"3577446101921159","gmtCreate":1614356511285,"gmtModify":1624169558813,"name":"Jasonyoyoo","pinyin":"jasonyoyoo","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":34,"tweetSize":12,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.08.20","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.03.28","exceedPercentage":"60.50%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.02.24","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":145060204,"gmtCreate":1626183546908,"gmtModify":1633929319495,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577446101921159","idStr":"3577446101921159"},"themes":[],"title":"","htmlText":"Good! Help like thanks","listText":"Good! Help like thanks","text":"Good! Help like thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/145060204","repostId":"2151555866","repostType":4,"isVote":1,"tweetType":1,"viewCount":2520,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":148887563,"gmtCreate":1625967362452,"gmtModify":1633931326346,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577446101921159","idStr":"3577446101921159"},"themes":[],"title":"","htmlText":"Best. Help like please&nbsp;","listText":"Best. Help like please&nbsp;","text":"Best. Help like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/148887563","repostId":"1176789091","repostType":4,"repost":{"id":"1176789091","kind":"news","pubTimestamp":1625966668,"share":"https://www.laohunote.com/m/news/1176789091?lang=zh_CN&edition=full","pubTime":"2021-07-11 09:24","market":"us","language":"en","title":"Could The iPad Be Apple’s Best Performer in Fiscal Q3?<blockquote>iPad 会成为苹果第三财季表现最好的产品吗？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1176789091","media":"TheStreet","summary":"The Apple Maven believes that the iPad could be Apple’s best performer in fiscal Q3. Here is why.\nTh","content":"<p>The Apple Maven believes that the iPad could be Apple’s best performer in fiscal Q3. Here is why.</p><p><blockquote>这位苹果专家认为，iPad 可能是苹果第三财季表现最好的产品。原因如下。</blockquote></p><p> The Apple Maven continues its preview of the Cupertino company’s fiscal third quarter earnings day. So far, we have discussed (1)Wall Street’s expectationsfor revenues and earnings and (2) the expected performance of the iPhone in the quarter.</p><p><blockquote>《苹果专家》继续对这家库比蒂诺公司第三财季财报日进行预览。到目前为止，我们已经讨论了 (1) 华尔街对收入和盈利的预期，以及 (2) iPhone 本季度的预期表现。</blockquote></p><p> Today, we address what could be Apple’s most successful product category in the third fiscal period of 2021: the iPad.</p><p><blockquote>今天，我们将讨论苹果在 2021 年第三财年最成功的产品类别：iPad。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/544b629337019373222b755bf493104b\" tg-width=\"1200\" tg-height=\"630\"><span>Figure 1: The latest iPad Pro model.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：最新的iPad Pro型号。</span></p></blockquote></p><p> The 2020 pandemic has made winners of tech companies that managed to capitalize on shifting consumer behavior – also known as the “stay at home” trends. This partially explains why iPad revenues have shot through the roof in the past several quarters: growth of at least 30% since fiscal Q2 last year.</p><p><blockquote>2020 年的大流行病让科技公司成为赢家，它们成功地利用了消费者行为的转变--也就是所谓的 “宅在家里 ”趋势。这在一定程度上解释了为什么 iPad 的收入在过去几个季度飙升：自去年第二财季以来至少增长了 30%。</blockquote></p><p> For starters,it has become increasingly obviousthat consumers are not returning to old spending habits, even as the COVID-19 crisis gets closer to an end. Therefore, I see no reason to doubt that iPad sales will impress once again this time, although the growth rate will be partially eclipsed by tough 2020 comps.</p><p><blockquote>首先，越来越明显的是，尽管 COVID-19 危机接近尾声，但消费者并没有恢复旧的消费习惯。因此，我认为没有理由怀疑iPad的销量这次将再次给人留下深刻印象，尽管增长率将被严峻的2020年业绩所部分掩盖。</blockquote></p><p> But the story does not end with the effects of the pandemic. The chart below shows that, since around 2017, Apple has been able to reignite demand for its tablets. Even in 2019, before the pandemic turned the world upside down, iPad sales had already been growing at a respectable 13% pace.</p><p><blockquote>但故事并没有随着疫情的影响而结束。下图显示，自2017年左右以来，苹果已经能够重新点燃对其平板电脑的需求。即使在2019年，在疫情颠覆世界之前，iPad的销量就已经以13%的可观速度增长。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b463e314374d0f90f3cedbd13430a0ae\" tg-width=\"631\" tg-height=\"377\"><span>Figure 2: iPad revenue in millions U.S dollars.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图2：以百万美元计的iPad收入。</span></p></blockquote></p><p> The rebirth of the tablet business, I will be frank,caught me by surprise. The phenomenon can be probably attributed to technological advancements allowing products like the iPad to better replace personal computers (more storage, better graphics, fast processor speed) and even smartphones (wider range of screen sizes, better cameras, introduction of 5G capability).</p><p><blockquote>坦白说，平板电脑业务的重生让我大吃一惊。这种现象可能归因于技术进步，使iPad等产品能够更好地取代个人电脑（更多的存储、更好的图形、更快的处理器速度），甚至智能手机（更广泛的屏幕尺寸、更好的摄像头、5G功能的引入）。</blockquote></p><p> Case in point, Research and Marketsbelievesthat tablet revenues across the industry will continue to grow at a CAGR of over 10% through 2023. This is quite an improvement from the days that iPad sales were declining sharply, between 2014 and 2018.</p><p><blockquote>例如，研究和市场认为，到 2023 年，整个行业的平板电脑收入将继续以超过 10% 的复合年增长率增长。这比2014年至2018年间iPad销量急剧下降的日子有了很大的进步。</blockquote></p><p> Lastly, Apple may have performed even better than its tablet competitors in the most recent quarter. First, the company has provenmore capable of managing its supply chain, which could be a plus during times of component shortages.</p><p><blockquote>最后，苹果在最近一个季度的表现可能比其平板电脑竞争对手还要好。首先，该公司已被证明更有能力管理其供应链，这在零部件短缺时期可能是一个优势。</blockquote></p><p> But also, Applereleased its new M1-equipped iPad Pro in April. Consumers have been more willing to pay up for better mobile devices lately, which might bode well for Apple’s top-of-the-line tablet. In fact, the iPad’s two percentage pointgainin market share in June could be explained by this product launch.</p><p><blockquote>此外，苹果在4月份发布了配备M1的新款iPad Pro。最近，消费者更愿意为更好的移动设备付费，这对苹果的顶级平板电脑来说可能是个好兆头。事实上，iPad 在 6 月份的市场份额增长了两个百分点，可以用这款产品的发布来解释。</blockquote></p><p> With the most recent tablet release, the entire iPad lineup (except for the less relevant mini version) is only about nine months old today. On the back of a strong product portfolio, the iPad could very well be the brightest star on Apple’s fiscal third quarter earnings day.</p><p><blockquote>随着最新的平板电脑发布，整个iPad系列（除了不太相关的迷你版）今天只有大约9个月的历史。凭借强大的产品组合，iPad 很可能成为苹果第三财季财报日最耀眼的明星。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could The iPad Be Apple’s Best Performer in Fiscal Q3?<blockquote>iPad 会成为苹果第三财季表现最好的产品吗？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould The iPad Be Apple’s Best Performer in Fiscal Q3?<blockquote>iPad 会成为苹果第三财季表现最好的产品吗？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">TheStreet</strong><span class=\"h-time small\">2021-07-11 09:24</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The Apple Maven believes that the iPad could be Apple’s best performer in fiscal Q3. Here is why.</p><p><blockquote>这位苹果专家认为，iPad 可能是苹果第三财季表现最好的产品。原因如下。</blockquote></p><p> The Apple Maven continues its preview of the Cupertino company’s fiscal third quarter earnings day. So far, we have discussed (1)Wall Street’s expectationsfor revenues and earnings and (2) the expected performance of the iPhone in the quarter.</p><p><blockquote>《苹果专家》继续对这家库比蒂诺公司第三财季财报日进行预览。到目前为止，我们已经讨论了 (1) 华尔街对收入和盈利的预期，以及 (2) iPhone 本季度的预期表现。</blockquote></p><p> Today, we address what could be Apple’s most successful product category in the third fiscal period of 2021: the iPad.</p><p><blockquote>今天，我们将讨论苹果在 2021 年第三财年最成功的产品类别：iPad。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/544b629337019373222b755bf493104b\" tg-width=\"1200\" tg-height=\"630\"><span>Figure 1: The latest iPad Pro model.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：最新的iPad Pro型号。</span></p></blockquote></p><p> The 2020 pandemic has made winners of tech companies that managed to capitalize on shifting consumer behavior – also known as the “stay at home” trends. This partially explains why iPad revenues have shot through the roof in the past several quarters: growth of at least 30% since fiscal Q2 last year.</p><p><blockquote>2020 年的大流行病让科技公司成为赢家，它们成功地利用了消费者行为的转变--也就是所谓的 “宅在家里 ”趋势。这在一定程度上解释了为什么 iPad 的收入在过去几个季度飙升：自去年第二财季以来至少增长了 30%。</blockquote></p><p> For starters,it has become increasingly obviousthat consumers are not returning to old spending habits, even as the COVID-19 crisis gets closer to an end. Therefore, I see no reason to doubt that iPad sales will impress once again this time, although the growth rate will be partially eclipsed by tough 2020 comps.</p><p><blockquote>首先，越来越明显的是，尽管 COVID-19 危机接近尾声，但消费者并没有恢复旧的消费习惯。因此，我认为没有理由怀疑iPad的销量这次将再次给人留下深刻印象，尽管增长率将被严峻的2020年业绩所部分掩盖。</blockquote></p><p> But the story does not end with the effects of the pandemic. The chart below shows that, since around 2017, Apple has been able to reignite demand for its tablets. Even in 2019, before the pandemic turned the world upside down, iPad sales had already been growing at a respectable 13% pace.</p><p><blockquote>但故事并没有随着疫情的影响而结束。下图显示，自2017年左右以来，苹果已经能够重新点燃对其平板电脑的需求。即使在2019年，在疫情颠覆世界之前，iPad的销量就已经以13%的可观速度增长。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b463e314374d0f90f3cedbd13430a0ae\" tg-width=\"631\" tg-height=\"377\"><span>Figure 2: iPad revenue in millions U.S dollars.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图2：以百万美元计的iPad收入。</span></p></blockquote></p><p> The rebirth of the tablet business, I will be frank,caught me by surprise. The phenomenon can be probably attributed to technological advancements allowing products like the iPad to better replace personal computers (more storage, better graphics, fast processor speed) and even smartphones (wider range of screen sizes, better cameras, introduction of 5G capability).</p><p><blockquote>坦白说，平板电脑业务的重生让我大吃一惊。这种现象可能归因于技术进步，使iPad等产品能够更好地取代个人电脑（更多的存储、更好的图形、更快的处理器速度），甚至智能手机（更广泛的屏幕尺寸、更好的摄像头、5G功能的引入）。</blockquote></p><p> Case in point, Research and Marketsbelievesthat tablet revenues across the industry will continue to grow at a CAGR of over 10% through 2023. This is quite an improvement from the days that iPad sales were declining sharply, between 2014 and 2018.</p><p><blockquote>例如，研究和市场认为，到 2023 年，整个行业的平板电脑收入将继续以超过 10% 的复合年增长率增长。这比2014年至2018年间iPad销量急剧下降的日子有了很大的进步。</blockquote></p><p> Lastly, Apple may have performed even better than its tablet competitors in the most recent quarter. First, the company has provenmore capable of managing its supply chain, which could be a plus during times of component shortages.</p><p><blockquote>最后，苹果在最近一个季度的表现可能比其平板电脑竞争对手还要好。首先，该公司已被证明更有能力管理其供应链，这在零部件短缺时期可能是一个优势。</blockquote></p><p> But also, Applereleased its new M1-equipped iPad Pro in April. Consumers have been more willing to pay up for better mobile devices lately, which might bode well for Apple’s top-of-the-line tablet. In fact, the iPad’s two percentage pointgainin market share in June could be explained by this product launch.</p><p><blockquote>此外，苹果在4月份发布了配备M1的新款iPad Pro。最近，消费者更愿意为更好的移动设备付费，这对苹果的顶级平板电脑来说可能是个好兆头。事实上，iPad 在 6 月份的市场份额增长了两个百分点，可以用这款产品的发布来解释。</blockquote></p><p> With the most recent tablet release, the entire iPad lineup (except for the less relevant mini version) is only about nine months old today. On the back of a strong product portfolio, the iPad could very well be the brightest star on Apple’s fiscal third quarter earnings day.</p><p><blockquote>随着最新的平板电脑发布，整个iPad系列（除了不太相关的迷你版）今天只有大约9个月的历史。凭借强大的产品组合，iPad 很可能成为苹果第三财季财报日最耀眼的明星。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/apple/other-products/could-the-ipad-be-apples-best-performer-in-fiscal-q3\">TheStreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.thestreet.com/apple/other-products/could-the-ipad-be-apples-best-performer-in-fiscal-q3","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176789091","content_text":"The Apple Maven believes that the iPad could be Apple’s best performer in fiscal Q3. Here is why.\nThe Apple Maven continues its preview of the Cupertino company’s fiscal third quarter earnings day. So far, we have discussed (1)Wall Street’s expectationsfor revenues and earnings and (2) the expected performance of the iPhone in the quarter.\nToday, we address what could be Apple’s most successful product category in the third fiscal period of 2021: the iPad.\nFigure 1: The latest iPad Pro model.\nThe 2020 pandemic has made winners of tech companies that managed to capitalize on shifting consumer behavior – also known as the “stay at home” trends. This partially explains why iPad revenues have shot through the roof in the past several quarters: growth of at least 30% since fiscal Q2 last year.\nFor starters,it has become increasingly obviousthat consumers are not returning to old spending habits, even as the COVID-19 crisis gets closer to an end. Therefore, I see no reason to doubt that iPad sales will impress once again this time, although the growth rate will be partially eclipsed by tough 2020 comps.\nBut the story does not end with the effects of the pandemic. The chart below shows that, since around 2017, Apple has been able to reignite demand for its tablets. Even in 2019, before the pandemic turned the world upside down, iPad sales had already been growing at a respectable 13% pace.\nFigure 2: iPad revenue in millions U.S dollars.\nThe rebirth of the tablet business, I will be frank,caught me by surprise. The phenomenon can be probably attributed to technological advancements allowing products like the iPad to better replace personal computers (more storage, better graphics, fast processor speed) and even smartphones (wider range of screen sizes, better cameras, introduction of 5G capability).\nCase in point, Research and Marketsbelievesthat tablet revenues across the industry will continue to grow at a CAGR of over 10% through 2023. This is quite an improvement from the days that iPad sales were declining sharply, between 2014 and 2018.\nLastly, Apple may have performed even better than its tablet competitors in the most recent quarter. First, the company has provenmore capable of managing its supply chain, which could be a plus during times of component shortages.\nBut also, Applereleased its new M1-equipped iPad Pro in April. Consumers have been more willing to pay up for better mobile devices lately, which might bode well for Apple’s top-of-the-line tablet. In fact, the iPad’s two percentage pointgainin market share in June could be explained by this product launch.\nWith the most recent tablet release, the entire iPad lineup (except for the less relevant mini version) is only about nine months old today. On the back of a strong product portfolio, the iPad could very well be the brightest star on Apple’s fiscal third quarter earnings day.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":1877,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":140462531,"gmtCreate":1625669179523,"gmtModify":1633938507201,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577446101921159","idStr":"3577446101921159"},"themes":[],"title":"","htmlText":"Like plz","listText":"Like plz","text":"Like plz","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/140462531","repostId":"1170890468","repostType":4,"repost":{"id":"1170890468","kind":"news","pubTimestamp":1625666670,"share":"https://www.laohunote.com/m/news/1170890468?lang=zh_CN&edition=full","pubTime":"2021-07-07 22:04","market":"us","language":"en","title":"Mark Wahlberg-backed F45 targets over $1.5 bln valuation in U.S. IPO<blockquote>马克·沃尔伯格支持的 F45 美国 IPO 估值超过 15 亿美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1170890468","media":"Reuters","summary":"July 7 (Reuters) - Mark Wahlberg-backed fitness chain F45 Training Holdings Inc is eyeing a valuatio","content":"<p>July 7 (Reuters) - Mark Wahlberg-backed fitness chain F45 Training Holdings Inc is eyeing a valuation of more than $1.5 billion in a U.S. initial public offering (IPO), months after terminating its merger with a blank-check company.</p><p><blockquote>路透社 7 月 7 日 - 马克·沃尔伯格 (Mark Wahlberg) 支持的健身连锁店 F45 Training Holdings Inc 在终止与一家空白支票公司的合并几个月后，预计在美国首次公开募股 (IPO) 中的估值将超过 15 亿美元。</blockquote></p><p> The Austin, Texas-based company was founded in 2013 in Australia and now has more than 1,500 studios, with about 2,800 franchises in 63 countries.</p><p><blockquote>这家总部位于德克萨斯州奥斯汀的公司于2013年在澳大利亚成立，目前拥有1500多家工作室，在63个国家拥有约2800家特许经营店。</blockquote></p><p> F45 said on Wednesday it was aiming to sell about 20.3 million shares priced between $15 and $17 apiece to raise up to $345 million. About 1.6 million shares in the IPO are being offered by the selling stockholder, the proceeds of which would not go to the company.</p><p><blockquote>F45 周三表示，计划出售约 2030 万股股票，每股价格在 15 美元至 17 美元之间，筹集至多 3.45 亿美元。出售股东将在 IPO 中提供约 160 万股股票，所得款项不会归公司所有。</blockquote></p><p> F45 agreed in June last year to merge with Crescent Acquisition Corp, a special purpose acquisition company, but later canceled the deal as the COVID-19 pandemic shut several of its studios.</p><p><blockquote>F45 于去年 6 月同意与特殊目的收购公司 Crescent Acquisition Corp 合并，但后来由于 COVID-19 大流行关闭了其几个工作室，该交易取消了。</blockquote></p><p> It posted an 11% drop in revenue for the year ended Dec. 31, 2020, with its net loss widening to $25.3 million from a loss of $12.6 million a year earlier.</p><p><blockquote>截至2020年12月31日的财年，该公司的收入下降了11%，净亏损从去年同期的1260万美元扩大到2530万美元。</blockquote></p><p> About 86% of the company's total studios were open as of March 31, according to its filing.</p><p><blockquote>根据该公司的文件，截至 3 月 31 日，该公司约 86% 的工作室已开放。</blockquote></p><p> The company is seeking to list on the New York Stock Exchange and will trade under the ticker symbol \"FXLV.\"</p><p><blockquote>该公司正在寻求在纽约证券交易所上市，股票代码为“FXLV”。</blockquote></p><p> Goldman Sachs and J.P. Morgan are the lead underwriters for the offering.</p><p><blockquote>高盛和摩根大通是此次发行的主承销商。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mark Wahlberg-backed F45 targets over $1.5 bln valuation in U.S. IPO<blockquote>马克·沃尔伯格支持的 F45 美国 IPO 估值超过 15 亿美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMark Wahlberg-backed F45 targets over $1.5 bln valuation in U.S. IPO<blockquote>马克·沃尔伯格支持的 F45 美国 IPO 估值超过 15 亿美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-07-07 22:04</span>\n</p>\n</h4>\n</header>\n<article>\n<p>July 7 (Reuters) - Mark Wahlberg-backed fitness chain F45 Training Holdings Inc is eyeing a valuation of more than $1.5 billion in a U.S. initial public offering (IPO), months after terminating its merger with a blank-check company.</p><p><blockquote>路透社 7 月 7 日 - 马克·沃尔伯格 (Mark Wahlberg) 支持的健身连锁店 F45 Training Holdings Inc 在终止与一家空白支票公司的合并几个月后，预计在美国首次公开募股 (IPO) 中的估值将超过 15 亿美元。</blockquote></p><p> The Austin, Texas-based company was founded in 2013 in Australia and now has more than 1,500 studios, with about 2,800 franchises in 63 countries.</p><p><blockquote>这家总部位于德克萨斯州奥斯汀的公司于2013年在澳大利亚成立，目前拥有1500多家工作室，在63个国家拥有约2800家特许经营店。</blockquote></p><p> F45 said on Wednesday it was aiming to sell about 20.3 million shares priced between $15 and $17 apiece to raise up to $345 million. About 1.6 million shares in the IPO are being offered by the selling stockholder, the proceeds of which would not go to the company.</p><p><blockquote>F45 周三表示，计划出售约 2030 万股股票，每股价格在 15 美元至 17 美元之间，筹集至多 3.45 亿美元。出售股东将在 IPO 中提供约 160 万股股票，所得款项不会归公司所有。</blockquote></p><p> F45 agreed in June last year to merge with Crescent Acquisition Corp, a special purpose acquisition company, but later canceled the deal as the COVID-19 pandemic shut several of its studios.</p><p><blockquote>F45 于去年 6 月同意与特殊目的收购公司 Crescent Acquisition Corp 合并，但后来由于 COVID-19 大流行关闭了其几个工作室，该交易取消了。</blockquote></p><p> It posted an 11% drop in revenue for the year ended Dec. 31, 2020, with its net loss widening to $25.3 million from a loss of $12.6 million a year earlier.</p><p><blockquote>截至2020年12月31日的财年，该公司的收入下降了11%，净亏损从去年同期的1260万美元扩大到2530万美元。</blockquote></p><p> About 86% of the company's total studios were open as of March 31, according to its filing.</p><p><blockquote>根据该公司的文件，截至 3 月 31 日，该公司约 86% 的工作室已开放。</blockquote></p><p> The company is seeking to list on the New York Stock Exchange and will trade under the ticker symbol \"FXLV.\"</p><p><blockquote>该公司正在寻求在纽约证券交易所上市，股票代码为“FXLV”。</blockquote></p><p> Goldman Sachs and J.P. Morgan are the lead underwriters for the offering.</p><p><blockquote>高盛和摩根大通是此次发行的主承销商。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/mark-wahlberg-backed-f45-targets-135813230.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index"},"source_url":"https://finance.yahoo.com/news/mark-wahlberg-backed-f45-targets-135813230.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170890468","content_text":"July 7 (Reuters) - Mark Wahlberg-backed fitness chain F45 Training Holdings Inc is eyeing a valuation of more than $1.5 billion in a U.S. initial public offering (IPO), months after terminating its merger with a blank-check company.\nThe Austin, Texas-based company was founded in 2013 in Australia and now has more than 1,500 studios, with about 2,800 franchises in 63 countries.\nF45 said on Wednesday it was aiming to sell about 20.3 million shares priced between $15 and $17 apiece to raise up to $345 million. About 1.6 million shares in the IPO are being offered by the selling stockholder, the proceeds of which would not go to the company.\nF45 agreed in June last year to merge with Crescent Acquisition Corp, a special purpose acquisition company, but later canceled the deal as the COVID-19 pandemic shut several of its studios.\nIt posted an 11% drop in revenue for the year ended Dec. 31, 2020, with its net loss widening to $25.3 million from a loss of $12.6 million a year earlier.\nAbout 86% of the company's total studios were open as of March 31, according to its filing.\nThe company is seeking to list on the New York Stock Exchange and will trade under the ticker symbol \"FXLV.\"\nGoldman Sachs and J.P. Morgan are the lead underwriters for the offering.","news_type":1,"symbols_score_info":{".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":2106,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":140466163,"gmtCreate":1625669147052,"gmtModify":1633938507922,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577446101921159","idStr":"3577446101921159"},"themes":[],"title":"","htmlText":"Sad","listText":"Sad","text":"Sad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/140466163","repostId":"1105988207","repostType":4,"isVote":1,"tweetType":1,"viewCount":1838,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":153504585,"gmtCreate":1625031414647,"gmtModify":1633945611388,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577446101921159","idStr":"3577446101921159"},"themes":[],"title":"","htmlText":"Like my comment please tq!&nbsp;","listText":"Like my comment please tq!&nbsp;","text":"Like my comment please tq!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/153504585","repostId":"1122418477","repostType":4,"isVote":1,"tweetType":1,"viewCount":2481,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":153504624,"gmtCreate":1625031390668,"gmtModify":1633945611510,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577446101921159","idStr":"3577446101921159"},"themes":[],"title":"","htmlText":"Very good&nbsp;","listText":"Very good&nbsp;","text":"Very good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/153504624","repostId":"1100317118","repostType":4,"repost":{"id":"1100317118","kind":"news","pubTimestamp":1625030487,"share":"https://www.laohunote.com/m/news/1100317118?lang=zh_CN&edition=full","pubTime":"2021-06-30 13:21","market":"us","language":"en","title":"These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday<blockquote>这两家纳斯达克生物技术公司周二做出了令人瞠目结舌的举动</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1100317118","media":"Motley Fool","summary":"The Nasdaq Composite(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The ind","content":"<p>The&nbsp;<b>Nasdaq Composite</b>(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The index kept up its momentum on Tuesday, rising just over 0.1% as of 12:30 p.m. EDT.</p><p><blockquote>这个<b>纳斯达克复合材料</b>（纳斯达克指数：^IXIC）最近表现良好，创下新的历史新高。该指数周二保持势头，截至美国东部时间中午 12:30，上涨略高于 0.1%。</blockquote></p><p> The Nasdaq is known for innovative companies, and a couple ofbiotech stocksgot a lot of attention on Tuesday.<b>Cerevel Therapeutics Holdings</b>(NASDAQ:CERE)got a nice push higher, but investors in&nbsp;<b>Sensei Biotherapeutics</b>(NASDAQ:SNSE)weren't as fortunate. Below, you'll get the details on both biotechs.</p><p><blockquote>纳斯达克以创新公司而闻名，周二，几只生物科技股受到了很多关注。<b>Cerevel Therapeutics控股</b>（纳斯达克股票代码：CERE）大幅上涨，但投资者<b>老师生物治疗</b>（纳斯达克股票代码：SNSE）没有那么幸运。下面，你会得到两种生物技术的详细信息。</blockquote></p><p> Cerevel serves up an early win</p><p><blockquote>Cerevel 早早获胜</blockquote></p><p> Shares of Cerevel were up 95% at middayon Tuesday after having more than doubled earlier in the session. The biotech company had good news from one of its key candidate treatments.</p><p><blockquote>Cerevel 股价周二中午上涨 95%，此前盘中早些时候上涨了一倍多。这家生物技术公司从其关键候选疗法之一传来了好消息。</blockquote></p><p> Cerevel announced positive results in its early-stage clinical trial of schizophrenia treatment CVL-231. The Cerevel treatment produced statistically significant improvements in a common scoring system for patients suffering from the disease compared to those who received a placebo. CVL-231 also produced encouraging safety and tolerability data that should be valuable in later-stage trials of the treatment.</p><p><blockquote>Cerevel宣布其精神分裂症治疗CVL-231的早期临床试验取得积极结果。与接受安慰剂的患者相比，Cerevel治疗在患有该疾病的患者的常见评分系统中产生了统计学上的显著改善。CVL-231还产生了令人鼓舞的安全性和耐受性数据，这些数据在治疗的后期试验中应该是有价值的。</blockquote></p><p> The company was pleased with the results. Cerevel's chief scientific officer sees the results as supporting the broader idea that targeted therapy for certain muscarinic receptors could work as a viable treatment for schizophrenia. At the same time, the executive sees the potential to avoid major side effects of other types of treatments for the disease.</p><p><blockquote>该公司对结果感到满意。Cerevel 的首席科学官认为这些结果支持了更广泛的观点，即针对某些毒蕈碱受体的靶向治疗可以作为精神分裂症的可行治疗方法。与此同时，这位高管看到了避免其他类型治疗该疾病的主要副作用的潜力。</blockquote></p><p> Cerevel came public less than a year ago through a SPAC merger with Arya Sciences Acquisition. With the stock far above anywhere it has traded since then, Cerevel is now firmly on the radar for biotech investors across the market.</p><p><blockquote>Cerevel 不到一年前通过与 Arya Sciences Acquisition 的 SPAC 合并上市。自那时以来，Cerevel 的股价远远高于其交易价格，现在已成为整个市场生物技术投资者的关注焦点。</blockquote></p><p> A disappointment for Sensei</p><p><blockquote>老师的失望</blockquote></p><p> Shares of Sensei Biotherapeutics moved the other way, falling more than 15%. Investors weren't pleased to learn of the immunotherapy specialist's strategic reprioritization of its treatment pipeline.</p><p><blockquote>Sensei Biotherapeutics 的股价则相反，下跌超过 15%。投资者对这家免疫疗法专家对其治疗管线的战略重新优先顺序感到不满。</blockquote></p><p> Sensei made the decision to shift its priority to its current product candidates, which include the ImmunoPhage treatment SNS-401-NG and the monoclonal antibody SNS-VISTA. By doing so, it hopes to stretch its available cash to cover costs through the first half of 2024.</p><p><blockquote>Sensei 决定将重点转移到目前的候选产品上，其中包括免疫噬菌体治疗 SNS-401-NG 和单克隆抗体 SNS-VISTA。通过这样做，它希望扩大可用现金来支付 2024 年上半年的成本。</blockquote></p><p> Unfortunately, what that means is that Sensei will no longer continue its SNS-301 program. After analyzing clinical activity and data specific to the single-antigen treatment, Sensei believes that it has drawn as much insight as it can from its first-generation candidate. Further action from Sensei should come shortly, with SNS-VISTA studies coming by the end of this year and SNS-401-NG getting further attention in the second half of 2022.</p><p><blockquote>不幸的是，这意味着Sensei将不再继续其SNS-301计划。在分析了单一抗原治疗的临床活动和特异性数据后，Sensei 相信它已经从第一代候选药物中获得了尽可能多的见解。Sensei应该很快就会采取进一步行动，SNS-VISTA研究将于今年年底进行，SNS-401-NG将在2022年下半年获得进一步关注。</blockquote></p><p> Sensei just came public in early February through an IPO that generated considerable interest. Investors were excited by the hope of personalizing cancer medications to treat disease more effectively, and Sensei sold 7 million shares at $19 per share to IPO investors. First-day excitement sent the stock as high as $26.50 per share, but those gains proved short-lived, and the stock has moved steadily lower ever since. It now stands at less than half its IPO price.</p><p><blockquote>Sensei 于 2 月初通过 IPO 上市，引起了相当大的兴趣。投资者对个性化癌症药物以更有效地治疗疾病的希望感到兴奋，Sensei 以每股 19 美元的价格向 IPO 投资者出售了 700 万股股票。首日的兴奋使该股高达每股 26.50 美元，但事实证明这些涨幅是短暂的，此后该股一直稳步走低。它现在的价格还不到IPO价格的一半。</blockquote></p><p> The biotech industry is full of winners and losers, and it's a high-risk area that can produce huge gains when things go well and massive losses when they don't. Sensei's future seems more in doubt after today's news than it was before, but investors are taking a closer look at what Cerevel might have to offer over the long run.</p><p><blockquote>生物技术行业充满了赢家和输家，这是一个高风险领域，当事情进展顺利时可能会产生巨大的收益，当事情进展不顺利时可能会产生巨大损失。今天的消息传出后，Sensei 的未来似乎比之前更加值得怀疑，但投资者正在仔细研究 Cerevel 从长远来看可能会提供什么。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday<blockquote>这两家纳斯达克生物技术公司周二做出了令人瞠目结舌的举动</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday<blockquote>这两家纳斯达克生物技术公司周二做出了令人瞠目结舌的举动</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-06-30 13:21</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The&nbsp;<b>Nasdaq Composite</b>(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The index kept up its momentum on Tuesday, rising just over 0.1% as of 12:30 p.m. EDT.</p><p><blockquote>这个<b>纳斯达克复合材料</b>（纳斯达克指数：^IXIC）最近表现良好，创下新的历史新高。该指数周二保持势头，截至美国东部时间中午 12:30，上涨略高于 0.1%。</blockquote></p><p> The Nasdaq is known for innovative companies, and a couple ofbiotech stocksgot a lot of attention on Tuesday.<b>Cerevel Therapeutics Holdings</b>(NASDAQ:CERE)got a nice push higher, but investors in&nbsp;<b>Sensei Biotherapeutics</b>(NASDAQ:SNSE)weren't as fortunate. Below, you'll get the details on both biotechs.</p><p><blockquote>纳斯达克以创新公司而闻名，周二，几只生物科技股受到了很多关注。<b>Cerevel Therapeutics控股</b>（纳斯达克股票代码：CERE）大幅上涨，但投资者<b>老师生物治疗</b>（纳斯达克股票代码：SNSE）没有那么幸运。下面，你会得到两种生物技术的详细信息。</blockquote></p><p> Cerevel serves up an early win</p><p><blockquote>Cerevel 早早获胜</blockquote></p><p> Shares of Cerevel were up 95% at middayon Tuesday after having more than doubled earlier in the session. The biotech company had good news from one of its key candidate treatments.</p><p><blockquote>Cerevel 股价周二中午上涨 95%，此前盘中早些时候上涨了一倍多。这家生物技术公司从其关键候选疗法之一传来了好消息。</blockquote></p><p> Cerevel announced positive results in its early-stage clinical trial of schizophrenia treatment CVL-231. The Cerevel treatment produced statistically significant improvements in a common scoring system for patients suffering from the disease compared to those who received a placebo. CVL-231 also produced encouraging safety and tolerability data that should be valuable in later-stage trials of the treatment.</p><p><blockquote>Cerevel宣布其精神分裂症治疗CVL-231的早期临床试验取得积极结果。与接受安慰剂的患者相比，Cerevel治疗在患有该疾病的患者的常见评分系统中产生了统计学上的显著改善。CVL-231还产生了令人鼓舞的安全性和耐受性数据，这些数据在治疗的后期试验中应该是有价值的。</blockquote></p><p> The company was pleased with the results. Cerevel's chief scientific officer sees the results as supporting the broader idea that targeted therapy for certain muscarinic receptors could work as a viable treatment for schizophrenia. At the same time, the executive sees the potential to avoid major side effects of other types of treatments for the disease.</p><p><blockquote>该公司对结果感到满意。Cerevel 的首席科学官认为这些结果支持了更广泛的观点，即针对某些毒蕈碱受体的靶向治疗可以作为精神分裂症的可行治疗方法。与此同时，这位高管看到了避免其他类型治疗该疾病的主要副作用的潜力。</blockquote></p><p> Cerevel came public less than a year ago through a SPAC merger with Arya Sciences Acquisition. With the stock far above anywhere it has traded since then, Cerevel is now firmly on the radar for biotech investors across the market.</p><p><blockquote>Cerevel 不到一年前通过与 Arya Sciences Acquisition 的 SPAC 合并上市。自那时以来，Cerevel 的股价远远高于其交易价格，现在已成为整个市场生物技术投资者的关注焦点。</blockquote></p><p> A disappointment for Sensei</p><p><blockquote>老师的失望</blockquote></p><p> Shares of Sensei Biotherapeutics moved the other way, falling more than 15%. Investors weren't pleased to learn of the immunotherapy specialist's strategic reprioritization of its treatment pipeline.</p><p><blockquote>Sensei Biotherapeutics 的股价则相反，下跌超过 15%。投资者对这家免疫疗法专家对其治疗管线的战略重新优先顺序感到不满。</blockquote></p><p> Sensei made the decision to shift its priority to its current product candidates, which include the ImmunoPhage treatment SNS-401-NG and the monoclonal antibody SNS-VISTA. By doing so, it hopes to stretch its available cash to cover costs through the first half of 2024.</p><p><blockquote>Sensei 决定将重点转移到目前的候选产品上，其中包括免疫噬菌体治疗 SNS-401-NG 和单克隆抗体 SNS-VISTA。通过这样做，它希望扩大可用现金来支付 2024 年上半年的成本。</blockquote></p><p> Unfortunately, what that means is that Sensei will no longer continue its SNS-301 program. After analyzing clinical activity and data specific to the single-antigen treatment, Sensei believes that it has drawn as much insight as it can from its first-generation candidate. Further action from Sensei should come shortly, with SNS-VISTA studies coming by the end of this year and SNS-401-NG getting further attention in the second half of 2022.</p><p><blockquote>不幸的是，这意味着Sensei将不再继续其SNS-301计划。在分析了单一抗原治疗的临床活动和特异性数据后，Sensei 相信它已经从第一代候选药物中获得了尽可能多的见解。Sensei应该很快就会采取进一步行动，SNS-VISTA研究将于今年年底进行，SNS-401-NG将在2022年下半年获得进一步关注。</blockquote></p><p> Sensei just came public in early February through an IPO that generated considerable interest. Investors were excited by the hope of personalizing cancer medications to treat disease more effectively, and Sensei sold 7 million shares at $19 per share to IPO investors. First-day excitement sent the stock as high as $26.50 per share, but those gains proved short-lived, and the stock has moved steadily lower ever since. It now stands at less than half its IPO price.</p><p><blockquote>Sensei 于 2 月初通过 IPO 上市，引起了相当大的兴趣。投资者对个性化癌症药物以更有效地治疗疾病的希望感到兴奋，Sensei 以每股 19 美元的价格向 IPO 投资者出售了 700 万股股票。首日的兴奋使该股高达每股 26.50 美元，但事实证明这些涨幅是短暂的，此后该股一直稳步走低。它现在的价格还不到IPO价格的一半。</blockquote></p><p> The biotech industry is full of winners and losers, and it's a high-risk area that can produce huge gains when things go well and massive losses when they don't. Sensei's future seems more in doubt after today's news than it was before, but investors are taking a closer look at what Cerevel might have to offer over the long run.</p><p><blockquote>生物技术行业充满了赢家和输家，这是一个高风险领域，当事情进展顺利时可能会产生巨大的收益，当事情进展不顺利时可能会产生巨大损失。今天的消息传出后，Sensei 的未来似乎比之前更加值得怀疑，但投资者正在仔细研究 Cerevel 从长远来看可能会提供什么。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/06/29/these-2-nasdaq-biotechs-made-eye-popping-moves-tue/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNSE":"Sensei Biotherapeutics, Inc."},"source_url":"https://www.fool.com/investing/2021/06/29/these-2-nasdaq-biotechs-made-eye-popping-moves-tue/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100317118","content_text":"The Nasdaq Composite(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The index kept up its momentum on Tuesday, rising just over 0.1% as of 12:30 p.m. EDT.\nThe Nasdaq is known for innovative companies, and a couple ofbiotech stocksgot a lot of attention on Tuesday.Cerevel Therapeutics Holdings(NASDAQ:CERE)got a nice push higher, but investors in Sensei Biotherapeutics(NASDAQ:SNSE)weren't as fortunate. Below, you'll get the details on both biotechs.\nCerevel serves up an early win\nShares of Cerevel were up 95% at middayon Tuesday after having more than doubled earlier in the session. The biotech company had good news from one of its key candidate treatments.\nCerevel announced positive results in its early-stage clinical trial of schizophrenia treatment CVL-231. The Cerevel treatment produced statistically significant improvements in a common scoring system for patients suffering from the disease compared to those who received a placebo. CVL-231 also produced encouraging safety and tolerability data that should be valuable in later-stage trials of the treatment.\nThe company was pleased with the results. Cerevel's chief scientific officer sees the results as supporting the broader idea that targeted therapy for certain muscarinic receptors could work as a viable treatment for schizophrenia. At the same time, the executive sees the potential to avoid major side effects of other types of treatments for the disease.\nCerevel came public less than a year ago through a SPAC merger with Arya Sciences Acquisition. With the stock far above anywhere it has traded since then, Cerevel is now firmly on the radar for biotech investors across the market.\nA disappointment for Sensei\nShares of Sensei Biotherapeutics moved the other way, falling more than 15%. Investors weren't pleased to learn of the immunotherapy specialist's strategic reprioritization of its treatment pipeline.\nSensei made the decision to shift its priority to its current product candidates, which include the ImmunoPhage treatment SNS-401-NG and the monoclonal antibody SNS-VISTA. By doing so, it hopes to stretch its available cash to cover costs through the first half of 2024.\nUnfortunately, what that means is that Sensei will no longer continue its SNS-301 program. After analyzing clinical activity and data specific to the single-antigen treatment, Sensei believes that it has drawn as much insight as it can from its first-generation candidate. Further action from Sensei should come shortly, with SNS-VISTA studies coming by the end of this year and SNS-401-NG getting further attention in the second half of 2022.\nSensei just came public in early February through an IPO that generated considerable interest. Investors were excited by the hope of personalizing cancer medications to treat disease more effectively, and Sensei sold 7 million shares at $19 per share to IPO investors. First-day excitement sent the stock as high as $26.50 per share, but those gains proved short-lived, and the stock has moved steadily lower ever since. It now stands at less than half its IPO price.\nThe biotech industry is full of winners and losers, and it's a high-risk area that can produce huge gains when things go well and massive losses when they don't. Sensei's future seems more in doubt after today's news than it was before, but investors are taking a closer look at what Cerevel might have to offer over the long run.","news_type":1,"symbols_score_info":{"SNSE":0.9,"CERE":0.9}},"isVote":1,"tweetType":1,"viewCount":3127,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":124213294,"gmtCreate":1624766543318,"gmtModify":1631885199145,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577446101921159","idStr":"3577446101921159"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/FSLY\">$Fastly, Inc.(FSLY)$</a>gooooood","listText":"<a href=\"https://laohu8.com/S/FSLY\">$Fastly, Inc.(FSLY)$</a>gooooood","text":"$Fastly, Inc.(FSLY)$gooooood","images":[{"img":"https://static.tigerbbs.com/0dd4679d3514860a127ce0cc05ed1e49","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/124213294","isVote":1,"tweetType":1,"viewCount":2236,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":164052522,"gmtCreate":1624162408666,"gmtModify":1634009968310,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577446101921159","idStr":"3577446101921159"},"themes":[],"title":"","htmlText":"Yay","listText":"Yay","text":"Yay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164052522","repostId":"1113942445","repostType":4,"isVote":1,"tweetType":1,"viewCount":2240,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164026119,"gmtCreate":1624162087931,"gmtModify":1634009979914,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577446101921159","idStr":"3577446101921159"},"themes":[],"title":"","htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164026119","repostId":"1126454279","repostType":4,"isVote":1,"tweetType":1,"viewCount":1918,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":106192454,"gmtCreate":1620091821478,"gmtModify":1634207894891,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577446101921159","idStr":"3577446101921159"},"themes":[],"title":"","htmlText":"😕","listText":"😕","text":"😕","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/106192454","repostId":"1147234999","repostType":4,"isVote":1,"tweetType":1,"viewCount":2314,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":106104426,"gmtCreate":1620091373865,"gmtModify":1634207900899,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577446101921159","idStr":"3577446101921159"},"themes":[],"title":"","htmlText":"❤️👍👍👍💪💪💪👌","listText":"❤️👍👍👍💪💪💪👌","text":"❤️👍👍👍💪💪💪👌","images":[{"img":"https://static.tigerbbs.com/cfce8e931057467a697bc94372436f0c","width":"1080","height":"2159"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/106104426","isVote":1,"tweetType":1,"viewCount":381,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":101713594,"gmtCreate":1619942518218,"gmtModify":1634208951134,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577446101921159","idStr":"3577446101921159"},"themes":[],"title":"","htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/101713594","repostId":"1146129324","repostType":4,"repost":{"id":"1146129324","kind":"news","pubTimestamp":1619795610,"share":"https://www.laohunote.com/m/news/1146129324?lang=zh_CN&edition=full","pubTime":"2021-04-30 23:13","market":"us","language":"en","title":"1 Question Tesla Investors Need to Ask Themselves<blockquote>特斯拉投资者需要问自己的一个问题</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1146129324","media":"Motley Fool","summary":"Electric-car companyTeslahas now produced a profit for seven consecutive quarters. Tesla managed aGAAPnet income of $438 million in the first quarter, up from just $16 million one-year prior. It would appear, at least at first glance, that the electric-vehicle  pioneer is on the right track in terms of profitability.The problem is that these profits aren't really coming from the cars that Tesla sells. The company currently generates hundreds of millions of dollars in pure profit each quarter fro","content":"<p>Electric-car company<b>Tesla</b>(NASDAQ:TSLA)has now produced a profit for seven consecutive quarters. Tesla managed aGAAPnet income of $438 million in the first quarter, up from just $16 million one-year prior. It would appear, at least at first glance, that the electric-vehicle (EV) pioneer is on the right track in terms of profitability.</p><p><blockquote>电动汽车公司<b>特斯拉</b>（纳斯达克股票代码：TSLA）现已连续七个季度实现盈利。特斯拉第一季度 aGAAPnet 收入为 4.38 亿美元，高于去年同期的 1600 万美元。至少乍一看，这家电动汽车（EV）先驱在盈利能力方面似乎走在了正确的轨道上。</blockquote></p><p> The problem is that these profits aren't really coming from the cars that Tesla sells. The company currently generates hundreds of millions of dollars in pure profit each quarter from the sale of regulatory credits, a side effect of other automakers not making enough zero-emission vehicles to meet regulatory requirements.</p><p><blockquote>问题是这些利润并不是真正来自特斯拉销售的汽车。该公司目前每个季度从出售监管积分中产生数亿美元的净利润，这是其他汽车制造商没有生产足够的零排放汽车来满足监管要求的副作用。</blockquote></p><p> Regulatory credit sales totaled $518 million in the first quarter, accounting for all of Tesla's profit and then some. This has been the case in previous quarters, as well. In fact, after backing out regulatory credits from Tesla's net income, the company has been unprofitable for six-straight quarters.</p><p><blockquote>第一季度监管信贷销售额总计 5.18 亿美元，占特斯拉的全部利润，然后是部分利润。前几个季度的情况也是如此。事实上，在从特斯拉净利润中扣除监管信贷后，该公司已连续六个季度未盈利。</blockquote></p><p> Tesla's bottom line got an additional boost in the first quarter from a gain onthe sale of<b>Bitcoin</b>to the tune of $101 million, which showed up as a reduction in costs. The picture doesn't look so rosy when both regulatory credits and Bitcoin gains are excluded:</p><p><blockquote>特斯拉第一季度的利润因销售收益而进一步提升<b>比特币</b>高达 1.01 亿美元，这体现在成本的降低上。当排除监管信贷和比特币收益时，情况看起来并不那么乐观：</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b0906160cab581f4c8a599b7d0965d34\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> DATA SOURCE: TESLA. CHART BY AUTHOR.</p><p><blockquote>数据来源：特斯拉。作者的图表。</blockquote></p><p> There's no question that Tesla's growth is impressive, but there's also no question that the core business of making and selling cars is not turning a profit. The question Tesla investors need to ask themselves is: If Tesla isn't profitable now, when there's little to no competition in electric vehicles in the United States, what's going to happen when a deluge of competition fromtraditional automakersarrives?</p><p><blockquote>毫无疑问，特斯拉的增长令人印象深刻，但也毫无疑问，制造和销售汽车的核心业务尚未盈利。特斯拉投资者需要问自己的问题是：如果特斯拉现在没有盈利，当美国电动汽车几乎没有竞争时，当传统汽车制造商的大量竞争到来时会发生什么？</blockquote></p><p> A ton of competition is coming</p><p><blockquote>大量的竞争即将到来</blockquote></p><p> Tesla's brand has a cult following, so some people will be buying Tesla vehicles regardless of the other options available. But that's not likely to be the case for most people.</p><p><blockquote>特斯拉品牌拥有一批狂热的追随者，因此无论有其他选择，一些人都会购买特斯拉汽车。但对大多数人来说，情况不太可能如此。</blockquote></p><p> The number of electric vehicles available for purchase in the U.S. is set to explode in the coming years.<b>General Motors</b>(NYSE:GM)is planning to launch 30 EVs globally by 2025, with two-thirds set to be sold in North America. The company is aiming to sell 1 million EVs annually in North America by 2025.</p><p><blockquote>未来几年，美国可供购买的电动汽车数量将呈爆炸式增长。<b>通用汽车</b>（纽约证券交易所股票代码：GM）计划到 2025 年在全球推出 30 款电动汽车，其中三分之二将在北美销售。该公司的目标是到 2025 年在北美每年销售 100 万辆电动汽车。</blockquote></p><p> Those models include electric versions of the company's GMC Hummer and Chevrolet Silverado pickup truck. Tesla has a loyal customer base, but so does GM. Someone who's been a GM truck buyer for years is likely to stick with GM when they decide to switch to an electric vehicle.</p><p><blockquote>这些车型包括该公司 GMC 悍马和雪佛兰索罗德皮卡车的电动版本。特斯拉拥有忠实的客户群，通用汽车也是如此。多年来一直是通用汽车卡车买家的人在决定改用电动汽车时可能会坚持使用通用汽车。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c651279799dfdf96552379a7b5d448a9\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> IMAGE SOURCE: GM.</p><p><blockquote>图片来源：GM。</blockquote></p><p> <b>Ford</b>(NYSE:F)is also pouring resources into electric vehicles, allocating $29 billion for electric and autonomous vehicles through 2025. The company's plans include anelectric version of its F-150 pickup truck, which should hit the production lines by mid-2022. Given GM's and Ford's plans, it will not be easy for Tesla to steal away market share in the lucrative pickup-truck segment.</p><p><blockquote><b>福特</b>（纽约证券交易所股票代码：F）也在向电动汽车投入资源，到 2025 年为电动和自动驾驶汽车拨款 290 亿美元。该公司的计划包括其 F-150 皮卡的电动版本，该版本将于 2022 年中期投产。鉴于通用汽车和福特的计划，特斯拉要在利润丰厚的皮卡领域抢走市场份额并不容易。</blockquote></p><p> Other car companies have big plans, as well.<b>Volkswagen</b>(OTC:VWAGY)already sells over 200,000 EVs annually andexpects that number to double this year. The company is aiming to sell roughly 2 million EVs annually by 2025 and expects to launch 70 EV models by 2030.<b>Toyota</b>(NYSE:TM)willlaunch 15 new electric vehicles by 2025, some of which will be under the new Toyota bZ sub-brand. The list goes on.</p><p><blockquote>其他汽车公司也有宏伟的计划。<b>大众汽车</b>（场外交易代码：VWAGY）每年电动汽车的销量已超过 20 万辆，预计今年这一数字将翻一番。该公司的目标是到 2025 年每年销售约 200 万辆电动汽车，并预计到 2030 年推出 70 款电动汽车车型。<b>丰田</b>（纽约证券交易所股票代码：TM）到 2025 年将推出 15 款新型电动汽车，其中一些将属于新的丰田 bZ 子品牌。这样的例子不胜枚举。</blockquote></p><p> Not only will all these electric vehicles provide consumers with a bevy of options beyond Tesla, but they'll also deprive Tesla of its regulatory-credit income as other automakers churn out an increasing number of EVs.</p><p><blockquote>所有这些电动汽车不仅会为消费者提供特斯拉以外的一系列选择，而且随着其他汽车制造商生产越来越多的电动汽车，它们还会剥夺特斯拉的监管信贷收入。</blockquote></p><p> None of this is to say that Tesla can't be successful in a world where it faces more competition. But turning a profit is is going to get harder with each passing year.</p><p><blockquote>这并不是说特斯拉不能在一个面临更多竞争的世界里取得成功。但随着时间的推移，盈利将变得越来越困难。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>1 Question Tesla Investors Need to Ask Themselves<blockquote>特斯拉投资者需要问自己的一个问题</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n1 Question Tesla Investors Need to Ask Themselves<blockquote>特斯拉投资者需要问自己的一个问题</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-04-30 23:13</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Electric-car company<b>Tesla</b>(NASDAQ:TSLA)has now produced a profit for seven consecutive quarters. Tesla managed aGAAPnet income of $438 million in the first quarter, up from just $16 million one-year prior. It would appear, at least at first glance, that the electric-vehicle (EV) pioneer is on the right track in terms of profitability.</p><p><blockquote>电动汽车公司<b>特斯拉</b>（纳斯达克股票代码：TSLA）现已连续七个季度实现盈利。特斯拉第一季度 aGAAPnet 收入为 4.38 亿美元，高于去年同期的 1600 万美元。至少乍一看，这家电动汽车（EV）先驱在盈利能力方面似乎走在了正确的轨道上。</blockquote></p><p> The problem is that these profits aren't really coming from the cars that Tesla sells. The company currently generates hundreds of millions of dollars in pure profit each quarter from the sale of regulatory credits, a side effect of other automakers not making enough zero-emission vehicles to meet regulatory requirements.</p><p><blockquote>问题是这些利润并不是真正来自特斯拉销售的汽车。该公司目前每个季度从出售监管积分中产生数亿美元的净利润，这是其他汽车制造商没有生产足够的零排放汽车来满足监管要求的副作用。</blockquote></p><p> Regulatory credit sales totaled $518 million in the first quarter, accounting for all of Tesla's profit and then some. This has been the case in previous quarters, as well. In fact, after backing out regulatory credits from Tesla's net income, the company has been unprofitable for six-straight quarters.</p><p><blockquote>第一季度监管信贷销售额总计 5.18 亿美元，占特斯拉的全部利润，然后是部分利润。前几个季度的情况也是如此。事实上，在从特斯拉净利润中扣除监管信贷后，该公司已连续六个季度未盈利。</blockquote></p><p> Tesla's bottom line got an additional boost in the first quarter from a gain onthe sale of<b>Bitcoin</b>to the tune of $101 million, which showed up as a reduction in costs. The picture doesn't look so rosy when both regulatory credits and Bitcoin gains are excluded:</p><p><blockquote>特斯拉第一季度的利润因销售收益而进一步提升<b>比特币</b>高达 1.01 亿美元，这体现在成本的降低上。当排除监管信贷和比特币收益时，情况看起来并不那么乐观：</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b0906160cab581f4c8a599b7d0965d34\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> DATA SOURCE: TESLA. CHART BY AUTHOR.</p><p><blockquote>数据来源：特斯拉。作者的图表。</blockquote></p><p> There's no question that Tesla's growth is impressive, but there's also no question that the core business of making and selling cars is not turning a profit. The question Tesla investors need to ask themselves is: If Tesla isn't profitable now, when there's little to no competition in electric vehicles in the United States, what's going to happen when a deluge of competition fromtraditional automakersarrives?</p><p><blockquote>毫无疑问，特斯拉的增长令人印象深刻，但也毫无疑问，制造和销售汽车的核心业务尚未盈利。特斯拉投资者需要问自己的问题是：如果特斯拉现在没有盈利，当美国电动汽车几乎没有竞争时，当传统汽车制造商的大量竞争到来时会发生什么？</blockquote></p><p> A ton of competition is coming</p><p><blockquote>大量的竞争即将到来</blockquote></p><p> Tesla's brand has a cult following, so some people will be buying Tesla vehicles regardless of the other options available. But that's not likely to be the case for most people.</p><p><blockquote>特斯拉品牌拥有一批狂热的追随者，因此无论有其他选择，一些人都会购买特斯拉汽车。但对大多数人来说，情况不太可能如此。</blockquote></p><p> The number of electric vehicles available for purchase in the U.S. is set to explode in the coming years.<b>General Motors</b>(NYSE:GM)is planning to launch 30 EVs globally by 2025, with two-thirds set to be sold in North America. The company is aiming to sell 1 million EVs annually in North America by 2025.</p><p><blockquote>未来几年，美国可供购买的电动汽车数量将呈爆炸式增长。<b>通用汽车</b>（纽约证券交易所股票代码：GM）计划到 2025 年在全球推出 30 款电动汽车，其中三分之二将在北美销售。该公司的目标是到 2025 年在北美每年销售 100 万辆电动汽车。</blockquote></p><p> Those models include electric versions of the company's GMC Hummer and Chevrolet Silverado pickup truck. Tesla has a loyal customer base, but so does GM. Someone who's been a GM truck buyer for years is likely to stick with GM when they decide to switch to an electric vehicle.</p><p><blockquote>这些车型包括该公司 GMC 悍马和雪佛兰索罗德皮卡车的电动版本。特斯拉拥有忠实的客户群，通用汽车也是如此。多年来一直是通用汽车卡车买家的人在决定改用电动汽车时可能会坚持使用通用汽车。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c651279799dfdf96552379a7b5d448a9\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> IMAGE SOURCE: GM.</p><p><blockquote>图片来源：GM。</blockquote></p><p> <b>Ford</b>(NYSE:F)is also pouring resources into electric vehicles, allocating $29 billion for electric and autonomous vehicles through 2025. The company's plans include anelectric version of its F-150 pickup truck, which should hit the production lines by mid-2022. Given GM's and Ford's plans, it will not be easy for Tesla to steal away market share in the lucrative pickup-truck segment.</p><p><blockquote><b>福特</b>（纽约证券交易所股票代码：F）也在向电动汽车投入资源，到 2025 年为电动和自动驾驶汽车拨款 290 亿美元。该公司的计划包括其 F-150 皮卡的电动版本，该版本将于 2022 年中期投产。鉴于通用汽车和福特的计划，特斯拉要在利润丰厚的皮卡领域抢走市场份额并不容易。</blockquote></p><p> Other car companies have big plans, as well.<b>Volkswagen</b>(OTC:VWAGY)already sells over 200,000 EVs annually andexpects that number to double this year. The company is aiming to sell roughly 2 million EVs annually by 2025 and expects to launch 70 EV models by 2030.<b>Toyota</b>(NYSE:TM)willlaunch 15 new electric vehicles by 2025, some of which will be under the new Toyota bZ sub-brand. The list goes on.</p><p><blockquote>其他汽车公司也有宏伟的计划。<b>大众汽车</b>（场外交易代码：VWAGY）每年电动汽车的销量已超过 20 万辆，预计今年这一数字将翻一番。该公司的目标是到 2025 年每年销售约 200 万辆电动汽车，并预计到 2030 年推出 70 款电动汽车车型。<b>丰田</b>（纽约证券交易所股票代码：TM）到 2025 年将推出 15 款新型电动汽车，其中一些将属于新的丰田 bZ 子品牌。这样的例子不胜枚举。</blockquote></p><p> Not only will all these electric vehicles provide consumers with a bevy of options beyond Tesla, but they'll also deprive Tesla of its regulatory-credit income as other automakers churn out an increasing number of EVs.</p><p><blockquote>所有这些电动汽车不仅会为消费者提供特斯拉以外的一系列选择，而且随着其他汽车制造商生产越来越多的电动汽车，它们还会剥夺特斯拉的监管信贷收入。</blockquote></p><p> None of this is to say that Tesla can't be successful in a world where it faces more competition. But turning a profit is is going to get harder with each passing year.</p><p><blockquote>这并不是说特斯拉不能在一个面临更多竞争的世界里取得成功。但随着时间的推移，盈利将变得越来越困难。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/04/30/1-question-tesla-investors-need-to-ask-themselves/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.fool.com/investing/2021/04/30/1-question-tesla-investors-need-to-ask-themselves/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146129324","content_text":"Electric-car companyTesla(NASDAQ:TSLA)has now produced a profit for seven consecutive quarters. Tesla managed aGAAPnet income of $438 million in the first quarter, up from just $16 million one-year prior. It would appear, at least at first glance, that the electric-vehicle (EV) pioneer is on the right track in terms of profitability.\nThe problem is that these profits aren't really coming from the cars that Tesla sells. The company currently generates hundreds of millions of dollars in pure profit each quarter from the sale of regulatory credits, a side effect of other automakers not making enough zero-emission vehicles to meet regulatory requirements.\nRegulatory credit sales totaled $518 million in the first quarter, accounting for all of Tesla's profit and then some. This has been the case in previous quarters, as well. In fact, after backing out regulatory credits from Tesla's net income, the company has been unprofitable for six-straight quarters.\nTesla's bottom line got an additional boost in the first quarter from a gain onthe sale ofBitcointo the tune of $101 million, which showed up as a reduction in costs. The picture doesn't look so rosy when both regulatory credits and Bitcoin gains are excluded:\n\nDATA SOURCE: TESLA. CHART BY AUTHOR.\nThere's no question that Tesla's growth is impressive, but there's also no question that the core business of making and selling cars is not turning a profit. The question Tesla investors need to ask themselves is: If Tesla isn't profitable now, when there's little to no competition in electric vehicles in the United States, what's going to happen when a deluge of competition fromtraditional automakersarrives?\nA ton of competition is coming\nTesla's brand has a cult following, so some people will be buying Tesla vehicles regardless of the other options available. But that's not likely to be the case for most people.\nThe number of electric vehicles available for purchase in the U.S. is set to explode in the coming years.General Motors(NYSE:GM)is planning to launch 30 EVs globally by 2025, with two-thirds set to be sold in North America. The company is aiming to sell 1 million EVs annually in North America by 2025.\nThose models include electric versions of the company's GMC Hummer and Chevrolet Silverado pickup truck. Tesla has a loyal customer base, but so does GM. Someone who's been a GM truck buyer for years is likely to stick with GM when they decide to switch to an electric vehicle.\n\nIMAGE SOURCE: GM.\nFord(NYSE:F)is also pouring resources into electric vehicles, allocating $29 billion for electric and autonomous vehicles through 2025. The company's plans include anelectric version of its F-150 pickup truck, which should hit the production lines by mid-2022. Given GM's and Ford's plans, it will not be easy for Tesla to steal away market share in the lucrative pickup-truck segment.\nOther car companies have big plans, as well.Volkswagen(OTC:VWAGY)already sells over 200,000 EVs annually andexpects that number to double this year. The company is aiming to sell roughly 2 million EVs annually by 2025 and expects to launch 70 EV models by 2030.Toyota(NYSE:TM)willlaunch 15 new electric vehicles by 2025, some of which will be under the new Toyota bZ sub-brand. The list goes on.\nNot only will all these electric vehicles provide consumers with a bevy of options beyond Tesla, but they'll also deprive Tesla of its regulatory-credit income as other automakers churn out an increasing number of EVs.\nNone of this is to say that Tesla can't be successful in a world where it faces more competition. But turning a profit is is going to get harder with each passing year.","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":545,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":145060204,"gmtCreate":1626183546908,"gmtModify":1633929319495,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577446101921159","authorIdStr":"3577446101921159"},"themes":[],"title":"","htmlText":"Good! Help like thanks","listText":"Good! Help like thanks","text":"Good! Help like thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/145060204","repostId":"2151555866","repostType":4,"isVote":1,"tweetType":1,"viewCount":2520,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":124213294,"gmtCreate":1624766543318,"gmtModify":1631885199145,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577446101921159","authorIdStr":"3577446101921159"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/FSLY\">$Fastly, Inc.(FSLY)$</a>gooooood","listText":"<a href=\"https://laohu8.com/S/FSLY\">$Fastly, Inc.(FSLY)$</a>gooooood","text":"$Fastly, Inc.(FSLY)$gooooood","images":[{"img":"https://static.tigerbbs.com/0dd4679d3514860a127ce0cc05ed1e49","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/124213294","isVote":1,"tweetType":1,"viewCount":2236,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":153504585,"gmtCreate":1625031414647,"gmtModify":1633945611388,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577446101921159","authorIdStr":"3577446101921159"},"themes":[],"title":"","htmlText":"Like my comment please tq!&nbsp;","listText":"Like my comment please tq!&nbsp;","text":"Like my comment please tq!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/153504585","repostId":"1122418477","repostType":4,"isVote":1,"tweetType":1,"viewCount":2481,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":148887563,"gmtCreate":1625967362452,"gmtModify":1633931326346,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577446101921159","authorIdStr":"3577446101921159"},"themes":[],"title":"","htmlText":"Best. Help like please&nbsp;","listText":"Best. Help like please&nbsp;","text":"Best. Help like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/148887563","repostId":"1176789091","repostType":4,"repost":{"id":"1176789091","kind":"news","pubTimestamp":1625966668,"share":"https://www.laohunote.com/m/news/1176789091?lang=zh_CN&edition=full","pubTime":"2021-07-11 09:24","market":"us","language":"en","title":"Could The iPad Be Apple’s Best Performer in Fiscal Q3?<blockquote>iPad 会成为苹果第三财季表现最好的产品吗？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1176789091","media":"TheStreet","summary":"The Apple Maven believes that the iPad could be Apple’s best performer in fiscal Q3. Here is why.\nTh","content":"<p>The Apple Maven believes that the iPad could be Apple’s best performer in fiscal Q3. Here is why.</p><p><blockquote>这位苹果专家认为，iPad 可能是苹果第三财季表现最好的产品。原因如下。</blockquote></p><p> The Apple Maven continues its preview of the Cupertino company’s fiscal third quarter earnings day. So far, we have discussed (1)Wall Street’s expectationsfor revenues and earnings and (2) the expected performance of the iPhone in the quarter.</p><p><blockquote>《苹果专家》继续对这家库比蒂诺公司第三财季财报日进行预览。到目前为止，我们已经讨论了 (1) 华尔街对收入和盈利的预期，以及 (2) iPhone 本季度的预期表现。</blockquote></p><p> Today, we address what could be Apple’s most successful product category in the third fiscal period of 2021: the iPad.</p><p><blockquote>今天，我们将讨论苹果在 2021 年第三财年最成功的产品类别：iPad。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/544b629337019373222b755bf493104b\" tg-width=\"1200\" tg-height=\"630\"><span>Figure 1: The latest iPad Pro model.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：最新的iPad Pro型号。</span></p></blockquote></p><p> The 2020 pandemic has made winners of tech companies that managed to capitalize on shifting consumer behavior – also known as the “stay at home” trends. This partially explains why iPad revenues have shot through the roof in the past several quarters: growth of at least 30% since fiscal Q2 last year.</p><p><blockquote>2020 年的大流行病让科技公司成为赢家，它们成功地利用了消费者行为的转变--也就是所谓的 “宅在家里 ”趋势。这在一定程度上解释了为什么 iPad 的收入在过去几个季度飙升：自去年第二财季以来至少增长了 30%。</blockquote></p><p> For starters,it has become increasingly obviousthat consumers are not returning to old spending habits, even as the COVID-19 crisis gets closer to an end. Therefore, I see no reason to doubt that iPad sales will impress once again this time, although the growth rate will be partially eclipsed by tough 2020 comps.</p><p><blockquote>首先，越来越明显的是，尽管 COVID-19 危机接近尾声，但消费者并没有恢复旧的消费习惯。因此，我认为没有理由怀疑iPad的销量这次将再次给人留下深刻印象，尽管增长率将被严峻的2020年业绩所部分掩盖。</blockquote></p><p> But the story does not end with the effects of the pandemic. The chart below shows that, since around 2017, Apple has been able to reignite demand for its tablets. Even in 2019, before the pandemic turned the world upside down, iPad sales had already been growing at a respectable 13% pace.</p><p><blockquote>但故事并没有随着疫情的影响而结束。下图显示，自2017年左右以来，苹果已经能够重新点燃对其平板电脑的需求。即使在2019年，在疫情颠覆世界之前，iPad的销量就已经以13%的可观速度增长。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b463e314374d0f90f3cedbd13430a0ae\" tg-width=\"631\" tg-height=\"377\"><span>Figure 2: iPad revenue in millions U.S dollars.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图2：以百万美元计的iPad收入。</span></p></blockquote></p><p> The rebirth of the tablet business, I will be frank,caught me by surprise. The phenomenon can be probably attributed to technological advancements allowing products like the iPad to better replace personal computers (more storage, better graphics, fast processor speed) and even smartphones (wider range of screen sizes, better cameras, introduction of 5G capability).</p><p><blockquote>坦白说，平板电脑业务的重生让我大吃一惊。这种现象可能归因于技术进步，使iPad等产品能够更好地取代个人电脑（更多的存储、更好的图形、更快的处理器速度），甚至智能手机（更广泛的屏幕尺寸、更好的摄像头、5G功能的引入）。</blockquote></p><p> Case in point, Research and Marketsbelievesthat tablet revenues across the industry will continue to grow at a CAGR of over 10% through 2023. This is quite an improvement from the days that iPad sales were declining sharply, between 2014 and 2018.</p><p><blockquote>例如，研究和市场认为，到 2023 年，整个行业的平板电脑收入将继续以超过 10% 的复合年增长率增长。这比2014年至2018年间iPad销量急剧下降的日子有了很大的进步。</blockquote></p><p> Lastly, Apple may have performed even better than its tablet competitors in the most recent quarter. First, the company has provenmore capable of managing its supply chain, which could be a plus during times of component shortages.</p><p><blockquote>最后，苹果在最近一个季度的表现可能比其平板电脑竞争对手还要好。首先，该公司已被证明更有能力管理其供应链，这在零部件短缺时期可能是一个优势。</blockquote></p><p> But also, Applereleased its new M1-equipped iPad Pro in April. Consumers have been more willing to pay up for better mobile devices lately, which might bode well for Apple’s top-of-the-line tablet. In fact, the iPad’s two percentage pointgainin market share in June could be explained by this product launch.</p><p><blockquote>此外，苹果在4月份发布了配备M1的新款iPad Pro。最近，消费者更愿意为更好的移动设备付费，这对苹果的顶级平板电脑来说可能是个好兆头。事实上，iPad 在 6 月份的市场份额增长了两个百分点，可以用这款产品的发布来解释。</blockquote></p><p> With the most recent tablet release, the entire iPad lineup (except for the less relevant mini version) is only about nine months old today. On the back of a strong product portfolio, the iPad could very well be the brightest star on Apple’s fiscal third quarter earnings day.</p><p><blockquote>随着最新的平板电脑发布，整个iPad系列（除了不太相关的迷你版）今天只有大约9个月的历史。凭借强大的产品组合，iPad 很可能成为苹果第三财季财报日最耀眼的明星。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could The iPad Be Apple’s Best Performer in Fiscal Q3?<blockquote>iPad 会成为苹果第三财季表现最好的产品吗？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould The iPad Be Apple’s Best Performer in Fiscal Q3?<blockquote>iPad 会成为苹果第三财季表现最好的产品吗？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">TheStreet</strong><span class=\"h-time small\">2021-07-11 09:24</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The Apple Maven believes that the iPad could be Apple’s best performer in fiscal Q3. Here is why.</p><p><blockquote>这位苹果专家认为，iPad 可能是苹果第三财季表现最好的产品。原因如下。</blockquote></p><p> The Apple Maven continues its preview of the Cupertino company’s fiscal third quarter earnings day. So far, we have discussed (1)Wall Street’s expectationsfor revenues and earnings and (2) the expected performance of the iPhone in the quarter.</p><p><blockquote>《苹果专家》继续对这家库比蒂诺公司第三财季财报日进行预览。到目前为止，我们已经讨论了 (1) 华尔街对收入和盈利的预期，以及 (2) iPhone 本季度的预期表现。</blockquote></p><p> Today, we address what could be Apple’s most successful product category in the third fiscal period of 2021: the iPad.</p><p><blockquote>今天，我们将讨论苹果在 2021 年第三财年最成功的产品类别：iPad。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/544b629337019373222b755bf493104b\" tg-width=\"1200\" tg-height=\"630\"><span>Figure 1: The latest iPad Pro model.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：最新的iPad Pro型号。</span></p></blockquote></p><p> The 2020 pandemic has made winners of tech companies that managed to capitalize on shifting consumer behavior – also known as the “stay at home” trends. This partially explains why iPad revenues have shot through the roof in the past several quarters: growth of at least 30% since fiscal Q2 last year.</p><p><blockquote>2020 年的大流行病让科技公司成为赢家，它们成功地利用了消费者行为的转变--也就是所谓的 “宅在家里 ”趋势。这在一定程度上解释了为什么 iPad 的收入在过去几个季度飙升：自去年第二财季以来至少增长了 30%。</blockquote></p><p> For starters,it has become increasingly obviousthat consumers are not returning to old spending habits, even as the COVID-19 crisis gets closer to an end. Therefore, I see no reason to doubt that iPad sales will impress once again this time, although the growth rate will be partially eclipsed by tough 2020 comps.</p><p><blockquote>首先，越来越明显的是，尽管 COVID-19 危机接近尾声，但消费者并没有恢复旧的消费习惯。因此，我认为没有理由怀疑iPad的销量这次将再次给人留下深刻印象，尽管增长率将被严峻的2020年业绩所部分掩盖。</blockquote></p><p> But the story does not end with the effects of the pandemic. The chart below shows that, since around 2017, Apple has been able to reignite demand for its tablets. Even in 2019, before the pandemic turned the world upside down, iPad sales had already been growing at a respectable 13% pace.</p><p><blockquote>但故事并没有随着疫情的影响而结束。下图显示，自2017年左右以来，苹果已经能够重新点燃对其平板电脑的需求。即使在2019年，在疫情颠覆世界之前，iPad的销量就已经以13%的可观速度增长。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b463e314374d0f90f3cedbd13430a0ae\" tg-width=\"631\" tg-height=\"377\"><span>Figure 2: iPad revenue in millions U.S dollars.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图2：以百万美元计的iPad收入。</span></p></blockquote></p><p> The rebirth of the tablet business, I will be frank,caught me by surprise. The phenomenon can be probably attributed to technological advancements allowing products like the iPad to better replace personal computers (more storage, better graphics, fast processor speed) and even smartphones (wider range of screen sizes, better cameras, introduction of 5G capability).</p><p><blockquote>坦白说，平板电脑业务的重生让我大吃一惊。这种现象可能归因于技术进步，使iPad等产品能够更好地取代个人电脑（更多的存储、更好的图形、更快的处理器速度），甚至智能手机（更广泛的屏幕尺寸、更好的摄像头、5G功能的引入）。</blockquote></p><p> Case in point, Research and Marketsbelievesthat tablet revenues across the industry will continue to grow at a CAGR of over 10% through 2023. This is quite an improvement from the days that iPad sales were declining sharply, between 2014 and 2018.</p><p><blockquote>例如，研究和市场认为，到 2023 年，整个行业的平板电脑收入将继续以超过 10% 的复合年增长率增长。这比2014年至2018年间iPad销量急剧下降的日子有了很大的进步。</blockquote></p><p> Lastly, Apple may have performed even better than its tablet competitors in the most recent quarter. First, the company has provenmore capable of managing its supply chain, which could be a plus during times of component shortages.</p><p><blockquote>最后，苹果在最近一个季度的表现可能比其平板电脑竞争对手还要好。首先，该公司已被证明更有能力管理其供应链，这在零部件短缺时期可能是一个优势。</blockquote></p><p> But also, Applereleased its new M1-equipped iPad Pro in April. Consumers have been more willing to pay up for better mobile devices lately, which might bode well for Apple’s top-of-the-line tablet. In fact, the iPad’s two percentage pointgainin market share in June could be explained by this product launch.</p><p><blockquote>此外，苹果在4月份发布了配备M1的新款iPad Pro。最近，消费者更愿意为更好的移动设备付费，这对苹果的顶级平板电脑来说可能是个好兆头。事实上，iPad 在 6 月份的市场份额增长了两个百分点，可以用这款产品的发布来解释。</blockquote></p><p> With the most recent tablet release, the entire iPad lineup (except for the less relevant mini version) is only about nine months old today. On the back of a strong product portfolio, the iPad could very well be the brightest star on Apple’s fiscal third quarter earnings day.</p><p><blockquote>随着最新的平板电脑发布，整个iPad系列（除了不太相关的迷你版）今天只有大约9个月的历史。凭借强大的产品组合，iPad 很可能成为苹果第三财季财报日最耀眼的明星。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/apple/other-products/could-the-ipad-be-apples-best-performer-in-fiscal-q3\">TheStreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.thestreet.com/apple/other-products/could-the-ipad-be-apples-best-performer-in-fiscal-q3","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176789091","content_text":"The Apple Maven believes that the iPad could be Apple’s best performer in fiscal Q3. Here is why.\nThe Apple Maven continues its preview of the Cupertino company’s fiscal third quarter earnings day. So far, we have discussed (1)Wall Street’s expectationsfor revenues and earnings and (2) the expected performance of the iPhone in the quarter.\nToday, we address what could be Apple’s most successful product category in the third fiscal period of 2021: the iPad.\nFigure 1: The latest iPad Pro model.\nThe 2020 pandemic has made winners of tech companies that managed to capitalize on shifting consumer behavior – also known as the “stay at home” trends. This partially explains why iPad revenues have shot through the roof in the past several quarters: growth of at least 30% since fiscal Q2 last year.\nFor starters,it has become increasingly obviousthat consumers are not returning to old spending habits, even as the COVID-19 crisis gets closer to an end. Therefore, I see no reason to doubt that iPad sales will impress once again this time, although the growth rate will be partially eclipsed by tough 2020 comps.\nBut the story does not end with the effects of the pandemic. The chart below shows that, since around 2017, Apple has been able to reignite demand for its tablets. Even in 2019, before the pandemic turned the world upside down, iPad sales had already been growing at a respectable 13% pace.\nFigure 2: iPad revenue in millions U.S dollars.\nThe rebirth of the tablet business, I will be frank,caught me by surprise. The phenomenon can be probably attributed to technological advancements allowing products like the iPad to better replace personal computers (more storage, better graphics, fast processor speed) and even smartphones (wider range of screen sizes, better cameras, introduction of 5G capability).\nCase in point, Research and Marketsbelievesthat tablet revenues across the industry will continue to grow at a CAGR of over 10% through 2023. This is quite an improvement from the days that iPad sales were declining sharply, between 2014 and 2018.\nLastly, Apple may have performed even better than its tablet competitors in the most recent quarter. First, the company has provenmore capable of managing its supply chain, which could be a plus during times of component shortages.\nBut also, Applereleased its new M1-equipped iPad Pro in April. Consumers have been more willing to pay up for better mobile devices lately, which might bode well for Apple’s top-of-the-line tablet. In fact, the iPad’s two percentage pointgainin market share in June could be explained by this product launch.\nWith the most recent tablet release, the entire iPad lineup (except for the less relevant mini version) is only about nine months old today. On the back of a strong product portfolio, the iPad could very well be the brightest star on Apple’s fiscal third quarter earnings day.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":1877,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":140462531,"gmtCreate":1625669179523,"gmtModify":1633938507201,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577446101921159","authorIdStr":"3577446101921159"},"themes":[],"title":"","htmlText":"Like plz","listText":"Like plz","text":"Like plz","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/140462531","repostId":"1170890468","repostType":4,"repost":{"id":"1170890468","kind":"news","pubTimestamp":1625666670,"share":"https://www.laohunote.com/m/news/1170890468?lang=zh_CN&edition=full","pubTime":"2021-07-07 22:04","market":"us","language":"en","title":"Mark Wahlberg-backed F45 targets over $1.5 bln valuation in U.S. IPO<blockquote>马克·沃尔伯格支持的 F45 美国 IPO 估值超过 15 亿美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1170890468","media":"Reuters","summary":"July 7 (Reuters) - Mark Wahlberg-backed fitness chain F45 Training Holdings Inc is eyeing a valuatio","content":"<p>July 7 (Reuters) - Mark Wahlberg-backed fitness chain F45 Training Holdings Inc is eyeing a valuation of more than $1.5 billion in a U.S. initial public offering (IPO), months after terminating its merger with a blank-check company.</p><p><blockquote>路透社 7 月 7 日 - 马克·沃尔伯格 (Mark Wahlberg) 支持的健身连锁店 F45 Training Holdings Inc 在终止与一家空白支票公司的合并几个月后，预计在美国首次公开募股 (IPO) 中的估值将超过 15 亿美元。</blockquote></p><p> The Austin, Texas-based company was founded in 2013 in Australia and now has more than 1,500 studios, with about 2,800 franchises in 63 countries.</p><p><blockquote>这家总部位于德克萨斯州奥斯汀的公司于2013年在澳大利亚成立，目前拥有1500多家工作室，在63个国家拥有约2800家特许经营店。</blockquote></p><p> F45 said on Wednesday it was aiming to sell about 20.3 million shares priced between $15 and $17 apiece to raise up to $345 million. About 1.6 million shares in the IPO are being offered by the selling stockholder, the proceeds of which would not go to the company.</p><p><blockquote>F45 周三表示，计划出售约 2030 万股股票，每股价格在 15 美元至 17 美元之间，筹集至多 3.45 亿美元。出售股东将在 IPO 中提供约 160 万股股票，所得款项不会归公司所有。</blockquote></p><p> F45 agreed in June last year to merge with Crescent Acquisition Corp, a special purpose acquisition company, but later canceled the deal as the COVID-19 pandemic shut several of its studios.</p><p><blockquote>F45 于去年 6 月同意与特殊目的收购公司 Crescent Acquisition Corp 合并，但后来由于 COVID-19 大流行关闭了其几个工作室，该交易取消了。</blockquote></p><p> It posted an 11% drop in revenue for the year ended Dec. 31, 2020, with its net loss widening to $25.3 million from a loss of $12.6 million a year earlier.</p><p><blockquote>截至2020年12月31日的财年，该公司的收入下降了11%，净亏损从去年同期的1260万美元扩大到2530万美元。</blockquote></p><p> About 86% of the company's total studios were open as of March 31, according to its filing.</p><p><blockquote>根据该公司的文件，截至 3 月 31 日，该公司约 86% 的工作室已开放。</blockquote></p><p> The company is seeking to list on the New York Stock Exchange and will trade under the ticker symbol \"FXLV.\"</p><p><blockquote>该公司正在寻求在纽约证券交易所上市，股票代码为“FXLV”。</blockquote></p><p> Goldman Sachs and J.P. Morgan are the lead underwriters for the offering.</p><p><blockquote>高盛和摩根大通是此次发行的主承销商。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mark Wahlberg-backed F45 targets over $1.5 bln valuation in U.S. IPO<blockquote>马克·沃尔伯格支持的 F45 美国 IPO 估值超过 15 亿美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMark Wahlberg-backed F45 targets over $1.5 bln valuation in U.S. IPO<blockquote>马克·沃尔伯格支持的 F45 美国 IPO 估值超过 15 亿美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-07-07 22:04</span>\n</p>\n</h4>\n</header>\n<article>\n<p>July 7 (Reuters) - Mark Wahlberg-backed fitness chain F45 Training Holdings Inc is eyeing a valuation of more than $1.5 billion in a U.S. initial public offering (IPO), months after terminating its merger with a blank-check company.</p><p><blockquote>路透社 7 月 7 日 - 马克·沃尔伯格 (Mark Wahlberg) 支持的健身连锁店 F45 Training Holdings Inc 在终止与一家空白支票公司的合并几个月后，预计在美国首次公开募股 (IPO) 中的估值将超过 15 亿美元。</blockquote></p><p> The Austin, Texas-based company was founded in 2013 in Australia and now has more than 1,500 studios, with about 2,800 franchises in 63 countries.</p><p><blockquote>这家总部位于德克萨斯州奥斯汀的公司于2013年在澳大利亚成立，目前拥有1500多家工作室，在63个国家拥有约2800家特许经营店。</blockquote></p><p> F45 said on Wednesday it was aiming to sell about 20.3 million shares priced between $15 and $17 apiece to raise up to $345 million. About 1.6 million shares in the IPO are being offered by the selling stockholder, the proceeds of which would not go to the company.</p><p><blockquote>F45 周三表示，计划出售约 2030 万股股票，每股价格在 15 美元至 17 美元之间，筹集至多 3.45 亿美元。出售股东将在 IPO 中提供约 160 万股股票，所得款项不会归公司所有。</blockquote></p><p> F45 agreed in June last year to merge with Crescent Acquisition Corp, a special purpose acquisition company, but later canceled the deal as the COVID-19 pandemic shut several of its studios.</p><p><blockquote>F45 于去年 6 月同意与特殊目的收购公司 Crescent Acquisition Corp 合并，但后来由于 COVID-19 大流行关闭了其几个工作室，该交易取消了。</blockquote></p><p> It posted an 11% drop in revenue for the year ended Dec. 31, 2020, with its net loss widening to $25.3 million from a loss of $12.6 million a year earlier.</p><p><blockquote>截至2020年12月31日的财年，该公司的收入下降了11%，净亏损从去年同期的1260万美元扩大到2530万美元。</blockquote></p><p> About 86% of the company's total studios were open as of March 31, according to its filing.</p><p><blockquote>根据该公司的文件，截至 3 月 31 日，该公司约 86% 的工作室已开放。</blockquote></p><p> The company is seeking to list on the New York Stock Exchange and will trade under the ticker symbol \"FXLV.\"</p><p><blockquote>该公司正在寻求在纽约证券交易所上市，股票代码为“FXLV”。</blockquote></p><p> Goldman Sachs and J.P. Morgan are the lead underwriters for the offering.</p><p><blockquote>高盛和摩根大通是此次发行的主承销商。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/mark-wahlberg-backed-f45-targets-135813230.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index"},"source_url":"https://finance.yahoo.com/news/mark-wahlberg-backed-f45-targets-135813230.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170890468","content_text":"July 7 (Reuters) - Mark Wahlberg-backed fitness chain F45 Training Holdings Inc is eyeing a valuation of more than $1.5 billion in a U.S. initial public offering (IPO), months after terminating its merger with a blank-check company.\nThe Austin, Texas-based company was founded in 2013 in Australia and now has more than 1,500 studios, with about 2,800 franchises in 63 countries.\nF45 said on Wednesday it was aiming to sell about 20.3 million shares priced between $15 and $17 apiece to raise up to $345 million. About 1.6 million shares in the IPO are being offered by the selling stockholder, the proceeds of which would not go to the company.\nF45 agreed in June last year to merge with Crescent Acquisition Corp, a special purpose acquisition company, but later canceled the deal as the COVID-19 pandemic shut several of its studios.\nIt posted an 11% drop in revenue for the year ended Dec. 31, 2020, with its net loss widening to $25.3 million from a loss of $12.6 million a year earlier.\nAbout 86% of the company's total studios were open as of March 31, according to its filing.\nThe company is seeking to list on the New York Stock Exchange and will trade under the ticker symbol \"FXLV.\"\nGoldman Sachs and J.P. Morgan are the lead underwriters for the offering.","news_type":1,"symbols_score_info":{".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":2106,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":106192454,"gmtCreate":1620091821478,"gmtModify":1634207894891,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577446101921159","authorIdStr":"3577446101921159"},"themes":[],"title":"","htmlText":"😕","listText":"😕","text":"😕","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/106192454","repostId":"1147234999","repostType":4,"isVote":1,"tweetType":1,"viewCount":2314,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":140466163,"gmtCreate":1625669147052,"gmtModify":1633938507922,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577446101921159","authorIdStr":"3577446101921159"},"themes":[],"title":"","htmlText":"Sad","listText":"Sad","text":"Sad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/140466163","repostId":"1105988207","repostType":4,"isVote":1,"tweetType":1,"viewCount":1838,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164052522,"gmtCreate":1624162408666,"gmtModify":1634009968310,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577446101921159","authorIdStr":"3577446101921159"},"themes":[],"title":"","htmlText":"Yay","listText":"Yay","text":"Yay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164052522","repostId":"1113942445","repostType":4,"isVote":1,"tweetType":1,"viewCount":2240,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":153504624,"gmtCreate":1625031390668,"gmtModify":1633945611510,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577446101921159","authorIdStr":"3577446101921159"},"themes":[],"title":"","htmlText":"Very good&nbsp;","listText":"Very good&nbsp;","text":"Very good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/153504624","repostId":"1100317118","repostType":4,"repost":{"id":"1100317118","kind":"news","pubTimestamp":1625030487,"share":"https://www.laohunote.com/m/news/1100317118?lang=zh_CN&edition=full","pubTime":"2021-06-30 13:21","market":"us","language":"en","title":"These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday<blockquote>这两家纳斯达克生物技术公司周二做出了令人瞠目结舌的举动</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1100317118","media":"Motley Fool","summary":"The Nasdaq Composite(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The ind","content":"<p>The&nbsp;<b>Nasdaq Composite</b>(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The index kept up its momentum on Tuesday, rising just over 0.1% as of 12:30 p.m. EDT.</p><p><blockquote>这个<b>纳斯达克复合材料</b>（纳斯达克指数：^IXIC）最近表现良好，创下新的历史新高。该指数周二保持势头，截至美国东部时间中午 12:30，上涨略高于 0.1%。</blockquote></p><p> The Nasdaq is known for innovative companies, and a couple ofbiotech stocksgot a lot of attention on Tuesday.<b>Cerevel Therapeutics Holdings</b>(NASDAQ:CERE)got a nice push higher, but investors in&nbsp;<b>Sensei Biotherapeutics</b>(NASDAQ:SNSE)weren't as fortunate. Below, you'll get the details on both biotechs.</p><p><blockquote>纳斯达克以创新公司而闻名，周二，几只生物科技股受到了很多关注。<b>Cerevel Therapeutics控股</b>（纳斯达克股票代码：CERE）大幅上涨，但投资者<b>老师生物治疗</b>（纳斯达克股票代码：SNSE）没有那么幸运。下面，你会得到两种生物技术的详细信息。</blockquote></p><p> Cerevel serves up an early win</p><p><blockquote>Cerevel 早早获胜</blockquote></p><p> Shares of Cerevel were up 95% at middayon Tuesday after having more than doubled earlier in the session. The biotech company had good news from one of its key candidate treatments.</p><p><blockquote>Cerevel 股价周二中午上涨 95%，此前盘中早些时候上涨了一倍多。这家生物技术公司从其关键候选疗法之一传来了好消息。</blockquote></p><p> Cerevel announced positive results in its early-stage clinical trial of schizophrenia treatment CVL-231. The Cerevel treatment produced statistically significant improvements in a common scoring system for patients suffering from the disease compared to those who received a placebo. CVL-231 also produced encouraging safety and tolerability data that should be valuable in later-stage trials of the treatment.</p><p><blockquote>Cerevel宣布其精神分裂症治疗CVL-231的早期临床试验取得积极结果。与接受安慰剂的患者相比，Cerevel治疗在患有该疾病的患者的常见评分系统中产生了统计学上的显著改善。CVL-231还产生了令人鼓舞的安全性和耐受性数据，这些数据在治疗的后期试验中应该是有价值的。</blockquote></p><p> The company was pleased with the results. Cerevel's chief scientific officer sees the results as supporting the broader idea that targeted therapy for certain muscarinic receptors could work as a viable treatment for schizophrenia. At the same time, the executive sees the potential to avoid major side effects of other types of treatments for the disease.</p><p><blockquote>该公司对结果感到满意。Cerevel 的首席科学官认为这些结果支持了更广泛的观点，即针对某些毒蕈碱受体的靶向治疗可以作为精神分裂症的可行治疗方法。与此同时，这位高管看到了避免其他类型治疗该疾病的主要副作用的潜力。</blockquote></p><p> Cerevel came public less than a year ago through a SPAC merger with Arya Sciences Acquisition. With the stock far above anywhere it has traded since then, Cerevel is now firmly on the radar for biotech investors across the market.</p><p><blockquote>Cerevel 不到一年前通过与 Arya Sciences Acquisition 的 SPAC 合并上市。自那时以来，Cerevel 的股价远远高于其交易价格，现在已成为整个市场生物技术投资者的关注焦点。</blockquote></p><p> A disappointment for Sensei</p><p><blockquote>老师的失望</blockquote></p><p> Shares of Sensei Biotherapeutics moved the other way, falling more than 15%. Investors weren't pleased to learn of the immunotherapy specialist's strategic reprioritization of its treatment pipeline.</p><p><blockquote>Sensei Biotherapeutics 的股价则相反，下跌超过 15%。投资者对这家免疫疗法专家对其治疗管线的战略重新优先顺序感到不满。</blockquote></p><p> Sensei made the decision to shift its priority to its current product candidates, which include the ImmunoPhage treatment SNS-401-NG and the monoclonal antibody SNS-VISTA. By doing so, it hopes to stretch its available cash to cover costs through the first half of 2024.</p><p><blockquote>Sensei 决定将重点转移到目前的候选产品上，其中包括免疫噬菌体治疗 SNS-401-NG 和单克隆抗体 SNS-VISTA。通过这样做，它希望扩大可用现金来支付 2024 年上半年的成本。</blockquote></p><p> Unfortunately, what that means is that Sensei will no longer continue its SNS-301 program. After analyzing clinical activity and data specific to the single-antigen treatment, Sensei believes that it has drawn as much insight as it can from its first-generation candidate. Further action from Sensei should come shortly, with SNS-VISTA studies coming by the end of this year and SNS-401-NG getting further attention in the second half of 2022.</p><p><blockquote>不幸的是，这意味着Sensei将不再继续其SNS-301计划。在分析了单一抗原治疗的临床活动和特异性数据后，Sensei 相信它已经从第一代候选药物中获得了尽可能多的见解。Sensei应该很快就会采取进一步行动，SNS-VISTA研究将于今年年底进行，SNS-401-NG将在2022年下半年获得进一步关注。</blockquote></p><p> Sensei just came public in early February through an IPO that generated considerable interest. Investors were excited by the hope of personalizing cancer medications to treat disease more effectively, and Sensei sold 7 million shares at $19 per share to IPO investors. First-day excitement sent the stock as high as $26.50 per share, but those gains proved short-lived, and the stock has moved steadily lower ever since. It now stands at less than half its IPO price.</p><p><blockquote>Sensei 于 2 月初通过 IPO 上市，引起了相当大的兴趣。投资者对个性化癌症药物以更有效地治疗疾病的希望感到兴奋，Sensei 以每股 19 美元的价格向 IPO 投资者出售了 700 万股股票。首日的兴奋使该股高达每股 26.50 美元，但事实证明这些涨幅是短暂的，此后该股一直稳步走低。它现在的价格还不到IPO价格的一半。</blockquote></p><p> The biotech industry is full of winners and losers, and it's a high-risk area that can produce huge gains when things go well and massive losses when they don't. Sensei's future seems more in doubt after today's news than it was before, but investors are taking a closer look at what Cerevel might have to offer over the long run.</p><p><blockquote>生物技术行业充满了赢家和输家，这是一个高风险领域，当事情进展顺利时可能会产生巨大的收益，当事情进展不顺利时可能会产生巨大损失。今天的消息传出后，Sensei 的未来似乎比之前更加值得怀疑，但投资者正在仔细研究 Cerevel 从长远来看可能会提供什么。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday<blockquote>这两家纳斯达克生物技术公司周二做出了令人瞠目结舌的举动</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday<blockquote>这两家纳斯达克生物技术公司周二做出了令人瞠目结舌的举动</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-06-30 13:21</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The&nbsp;<b>Nasdaq Composite</b>(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The index kept up its momentum on Tuesday, rising just over 0.1% as of 12:30 p.m. EDT.</p><p><blockquote>这个<b>纳斯达克复合材料</b>（纳斯达克指数：^IXIC）最近表现良好，创下新的历史新高。该指数周二保持势头，截至美国东部时间中午 12:30，上涨略高于 0.1%。</blockquote></p><p> The Nasdaq is known for innovative companies, and a couple ofbiotech stocksgot a lot of attention on Tuesday.<b>Cerevel Therapeutics Holdings</b>(NASDAQ:CERE)got a nice push higher, but investors in&nbsp;<b>Sensei Biotherapeutics</b>(NASDAQ:SNSE)weren't as fortunate. Below, you'll get the details on both biotechs.</p><p><blockquote>纳斯达克以创新公司而闻名，周二，几只生物科技股受到了很多关注。<b>Cerevel Therapeutics控股</b>（纳斯达克股票代码：CERE）大幅上涨，但投资者<b>老师生物治疗</b>（纳斯达克股票代码：SNSE）没有那么幸运。下面，你会得到两种生物技术的详细信息。</blockquote></p><p> Cerevel serves up an early win</p><p><blockquote>Cerevel 早早获胜</blockquote></p><p> Shares of Cerevel were up 95% at middayon Tuesday after having more than doubled earlier in the session. The biotech company had good news from one of its key candidate treatments.</p><p><blockquote>Cerevel 股价周二中午上涨 95%，此前盘中早些时候上涨了一倍多。这家生物技术公司从其关键候选疗法之一传来了好消息。</blockquote></p><p> Cerevel announced positive results in its early-stage clinical trial of schizophrenia treatment CVL-231. The Cerevel treatment produced statistically significant improvements in a common scoring system for patients suffering from the disease compared to those who received a placebo. CVL-231 also produced encouraging safety and tolerability data that should be valuable in later-stage trials of the treatment.</p><p><blockquote>Cerevel宣布其精神分裂症治疗CVL-231的早期临床试验取得积极结果。与接受安慰剂的患者相比，Cerevel治疗在患有该疾病的患者的常见评分系统中产生了统计学上的显著改善。CVL-231还产生了令人鼓舞的安全性和耐受性数据，这些数据在治疗的后期试验中应该是有价值的。</blockquote></p><p> The company was pleased with the results. Cerevel's chief scientific officer sees the results as supporting the broader idea that targeted therapy for certain muscarinic receptors could work as a viable treatment for schizophrenia. At the same time, the executive sees the potential to avoid major side effects of other types of treatments for the disease.</p><p><blockquote>该公司对结果感到满意。Cerevel 的首席科学官认为这些结果支持了更广泛的观点，即针对某些毒蕈碱受体的靶向治疗可以作为精神分裂症的可行治疗方法。与此同时，这位高管看到了避免其他类型治疗该疾病的主要副作用的潜力。</blockquote></p><p> Cerevel came public less than a year ago through a SPAC merger with Arya Sciences Acquisition. With the stock far above anywhere it has traded since then, Cerevel is now firmly on the radar for biotech investors across the market.</p><p><blockquote>Cerevel 不到一年前通过与 Arya Sciences Acquisition 的 SPAC 合并上市。自那时以来，Cerevel 的股价远远高于其交易价格，现在已成为整个市场生物技术投资者的关注焦点。</blockquote></p><p> A disappointment for Sensei</p><p><blockquote>老师的失望</blockquote></p><p> Shares of Sensei Biotherapeutics moved the other way, falling more than 15%. Investors weren't pleased to learn of the immunotherapy specialist's strategic reprioritization of its treatment pipeline.</p><p><blockquote>Sensei Biotherapeutics 的股价则相反，下跌超过 15%。投资者对这家免疫疗法专家对其治疗管线的战略重新优先顺序感到不满。</blockquote></p><p> Sensei made the decision to shift its priority to its current product candidates, which include the ImmunoPhage treatment SNS-401-NG and the monoclonal antibody SNS-VISTA. By doing so, it hopes to stretch its available cash to cover costs through the first half of 2024.</p><p><blockquote>Sensei 决定将重点转移到目前的候选产品上，其中包括免疫噬菌体治疗 SNS-401-NG 和单克隆抗体 SNS-VISTA。通过这样做，它希望扩大可用现金来支付 2024 年上半年的成本。</blockquote></p><p> Unfortunately, what that means is that Sensei will no longer continue its SNS-301 program. After analyzing clinical activity and data specific to the single-antigen treatment, Sensei believes that it has drawn as much insight as it can from its first-generation candidate. Further action from Sensei should come shortly, with SNS-VISTA studies coming by the end of this year and SNS-401-NG getting further attention in the second half of 2022.</p><p><blockquote>不幸的是，这意味着Sensei将不再继续其SNS-301计划。在分析了单一抗原治疗的临床活动和特异性数据后，Sensei 相信它已经从第一代候选药物中获得了尽可能多的见解。Sensei应该很快就会采取进一步行动，SNS-VISTA研究将于今年年底进行，SNS-401-NG将在2022年下半年获得进一步关注。</blockquote></p><p> Sensei just came public in early February through an IPO that generated considerable interest. Investors were excited by the hope of personalizing cancer medications to treat disease more effectively, and Sensei sold 7 million shares at $19 per share to IPO investors. First-day excitement sent the stock as high as $26.50 per share, but those gains proved short-lived, and the stock has moved steadily lower ever since. It now stands at less than half its IPO price.</p><p><blockquote>Sensei 于 2 月初通过 IPO 上市，引起了相当大的兴趣。投资者对个性化癌症药物以更有效地治疗疾病的希望感到兴奋，Sensei 以每股 19 美元的价格向 IPO 投资者出售了 700 万股股票。首日的兴奋使该股高达每股 26.50 美元，但事实证明这些涨幅是短暂的，此后该股一直稳步走低。它现在的价格还不到IPO价格的一半。</blockquote></p><p> The biotech industry is full of winners and losers, and it's a high-risk area that can produce huge gains when things go well and massive losses when they don't. Sensei's future seems more in doubt after today's news than it was before, but investors are taking a closer look at what Cerevel might have to offer over the long run.</p><p><blockquote>生物技术行业充满了赢家和输家，这是一个高风险领域，当事情进展顺利时可能会产生巨大的收益，当事情进展不顺利时可能会产生巨大损失。今天的消息传出后，Sensei 的未来似乎比之前更加值得怀疑，但投资者正在仔细研究 Cerevel 从长远来看可能会提供什么。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/06/29/these-2-nasdaq-biotechs-made-eye-popping-moves-tue/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNSE":"Sensei Biotherapeutics, Inc."},"source_url":"https://www.fool.com/investing/2021/06/29/these-2-nasdaq-biotechs-made-eye-popping-moves-tue/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100317118","content_text":"The Nasdaq Composite(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The index kept up its momentum on Tuesday, rising just over 0.1% as of 12:30 p.m. EDT.\nThe Nasdaq is known for innovative companies, and a couple ofbiotech stocksgot a lot of attention on Tuesday.Cerevel Therapeutics Holdings(NASDAQ:CERE)got a nice push higher, but investors in Sensei Biotherapeutics(NASDAQ:SNSE)weren't as fortunate. Below, you'll get the details on both biotechs.\nCerevel serves up an early win\nShares of Cerevel were up 95% at middayon Tuesday after having more than doubled earlier in the session. The biotech company had good news from one of its key candidate treatments.\nCerevel announced positive results in its early-stage clinical trial of schizophrenia treatment CVL-231. The Cerevel treatment produced statistically significant improvements in a common scoring system for patients suffering from the disease compared to those who received a placebo. CVL-231 also produced encouraging safety and tolerability data that should be valuable in later-stage trials of the treatment.\nThe company was pleased with the results. Cerevel's chief scientific officer sees the results as supporting the broader idea that targeted therapy for certain muscarinic receptors could work as a viable treatment for schizophrenia. At the same time, the executive sees the potential to avoid major side effects of other types of treatments for the disease.\nCerevel came public less than a year ago through a SPAC merger with Arya Sciences Acquisition. With the stock far above anywhere it has traded since then, Cerevel is now firmly on the radar for biotech investors across the market.\nA disappointment for Sensei\nShares of Sensei Biotherapeutics moved the other way, falling more than 15%. Investors weren't pleased to learn of the immunotherapy specialist's strategic reprioritization of its treatment pipeline.\nSensei made the decision to shift its priority to its current product candidates, which include the ImmunoPhage treatment SNS-401-NG and the monoclonal antibody SNS-VISTA. By doing so, it hopes to stretch its available cash to cover costs through the first half of 2024.\nUnfortunately, what that means is that Sensei will no longer continue its SNS-301 program. After analyzing clinical activity and data specific to the single-antigen treatment, Sensei believes that it has drawn as much insight as it can from its first-generation candidate. Further action from Sensei should come shortly, with SNS-VISTA studies coming by the end of this year and SNS-401-NG getting further attention in the second half of 2022.\nSensei just came public in early February through an IPO that generated considerable interest. Investors were excited by the hope of personalizing cancer medications to treat disease more effectively, and Sensei sold 7 million shares at $19 per share to IPO investors. First-day excitement sent the stock as high as $26.50 per share, but those gains proved short-lived, and the stock has moved steadily lower ever since. It now stands at less than half its IPO price.\nThe biotech industry is full of winners and losers, and it's a high-risk area that can produce huge gains when things go well and massive losses when they don't. Sensei's future seems more in doubt after today's news than it was before, but investors are taking a closer look at what Cerevel might have to offer over the long run.","news_type":1,"symbols_score_info":{"SNSE":0.9,"CERE":0.9}},"isVote":1,"tweetType":1,"viewCount":3127,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164026119,"gmtCreate":1624162087931,"gmtModify":1634009979914,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577446101921159","authorIdStr":"3577446101921159"},"themes":[],"title":"","htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164026119","repostId":"1126454279","repostType":4,"isVote":1,"tweetType":1,"viewCount":1918,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}